

**Date of preparation:** June 16, 2025

**Dawn L. Hershman, MD, MS**

**ACADEMIC APPOINTMENTS, HOSPITAL APPOINTMENTS, AND OTHER WORK EXPERIENCE**

---

**Academic Appointments**

---

07/2015 - present	<b>Columbia University College of Physicians &amp; Surgeons</b> Professor of Medicine and Epidemiology with tenure	New York, NY
07/2010– 06/2015	<b>Columbia University College of Physicians &amp; Surgeons</b> Associate Professor of Medicine and Epidemiology with tenure	New York, NY
07/2004 – 06/2010	<b>Columbia University Mailman School of Public Health</b> Assistant Professor of Epidemiology	New York, NY
07/2001 – 06/2010	<b>Columbia University College of Physicians &amp; Surgeons</b> Assistant Professor of Medicine	New York, NY

**Hospital Appointments**

---

07/2015 - present	<b>New York-Presbyterian/Columbia University Medical Center</b> Attending	New York, NY
07/2010– 06/2015	<b>New York-Presbyterian/Columbia University Medical Center</b> Associate Attending	New York, NY
07/2001 – 06/2010	<b>New York-Presbyterian/Columbia University Medical Center</b> Assistant Attending	New York, NY

**EDUCATION**

---

07/1999 – 05/2001	<b>Columbia University, Mailman School of Public Health</b> MS, May 2001	New York, NY
08/1990 – 05/1994	<b>Albert Einstein College of Medicine</b> MD, May 1994	New York, NY
08/1984 – 05/1987	<b>University of California, Los Angeles</b> BA, Psychology, May 1987	Los Angeles, CA

**TRAINING**

---

07/2000 – 06/2001	<b>Columbia University School of Public Health, New York, NY,</b> T32 Fellow. Cancer Epidemiology, Biostatistics, Environmental Sciences Training Program	New York, NY
07/2008– 06/2001	<b>Department of Medicine, Columbia University</b> Hematology/Oncology Clinical Fellow	New York, NY
07/1997 – 06/1998	<b>Department of Medicine, Columbia University</b> Internal Medicine Chief Resident	New York, NY
07/1994 – 06/1997	<b>Department of Medicine, Columbia University</b> Internal Medicine Intern/Resident	New York, NY

**LICENSURE AND BOARD CERTIFICATION**

---

LICENSURE: NY 201353

BOARD QUALIFICATION: Internal Medicine (Recertification 2017)  
Medical Oncology (Recertification 2022)

## HONORS AND AWARDS

---

2025 American Society of Clinical Oncology David Karnofsky Science of Oncology Award  
2024 Irene and Arthur Fishberg Prize  
2023 Witten Family Professor of Medicine  
2022 American Cancer Society Fostering Innovation Award  
2021 Giant of Cancer Care in Supportive Care, MJH Lifesciences  
2021 Association of American Physicians (AAP)  
2021 CUIMC Mentor of the Year award  
2025 New York Magazine "Best Doctors" (2015 - present)  
2020 American Cancer Society Research Professor  
2020 ASCO/Conquer Cancer Women Who Conquer Cancer Mentorship Award  
2016 Fellow of the American Society of Clinical Oncology  
2016 Komen Scholar Award  
2015 American Society of Clinical Investigation (ASCI)  
2015 American Society of Clinical Oncology Research Professorship  
2010 Avon Breast Cancer Medical Advancement Award  
2009 American Society of Clinical Oncology Leadership Development Awardee  
2006 Ewig Award for Teaching Excellence  
1994 Zelig Rosen Award for Excellence in Cardiology Research  
1994 Janet M Glasgow Achievement Award  
1994 Alpha Omega Alpha

## ACADEMIC SERVICE

---

04/2025 – Present	Chief, Division of Hematology and Oncology, Columbia University Medical Center	New York, NY
01/2023 – 04/2025	Interim Chief, Division of Hematology and Oncology, Columbia University Medical Center	New York, NY
07/2022 – Present	Deputy Director, Herbert Irving Comprehensive Cancer Center	New York, NY
07/2022 – 12/2022	Vice-Chief, Division Medical Oncology, Columbia University Medical Center	New York, NY
07/2015 – Present	Vice-Chair, NCI SWOG NCORP Research Base	New York, NY
07/2002 – Present	Director, Breast Oncology, Department of Medicine, Columbia University	New York, NY
07/2019 – Present	Breast Cancer Team Leader, Herbert Irving Comprehensive Cancer Center	New York, NY
07/2012 – 2019	Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center	New York, NY
07/2013 – Present	Senior Leadership Team, Herbert Irving Comprehensive Cancer Center	New York, NY
07/2001 – 2007	Director, Oncology Fellowship Program, Department of Medicine, Columbia University	New York, NY

## ADMINISTRATIVE RESPONSIBILITIES

2020-Present	HICCC Translational Clinical Research Committee - Member
2020-Present	Fiscal Support Sub-Committee of the TCRC/HICCC
2020	Search Committee Chair: Irving Population Science Professorship
2015-	Search Committee: Chair Radiation Oncology
2012- Present	Cancer Center, Senior Leadership Team

2011-12	Deans Strategic Planning Committee
2011,2021	Columbia Summer Research Institute (CSRI), Mentor.
2008-	Clinical Trials Advisory Committee, CUMC, Member.
2007- Present	Executive Committee, Department of Medicine
2007	Deans Committee for Conflict of Interest Policy: College of Physicians and Surgeons.
2007	Search Committee Junior Faculty Subgroup: Department Chair of Medicine, CUMC
2007	Search Committee: Chief of Breast Surgery, CUMC.
2007-Present	Scientific Advisory Committee, CTSA, Columbia University
1998 - 2000	Joint Residency Program Committee, New York Presbyterian Hospital, Member.
2001 - Present	Fellowship Selection Committee, Columbia University, Department of Medicine, Member
1997 - Present	Residency Selection Committee, Columbia University, Department of Medicine, Member

## **PROFESSIONAL ORGANIZATIONS AND SOCIETIES**

### MEMBERSHIPS AND POSITIONS

American Society of Clinical Investigation  
 American College of Physicians.  
 American Society of Clinical Oncology.  
 American Association for Cancer Research  
 Southwest Oncology Group (SWOG)

### JOURNAL REVIEWER

JAMA  
 JAMA Oncology  
 Journal of Cancer Survivorship  
 Journal of Oncology Practice  
 Breast Cancer Research and Treatment  
 British Journal of Cancer  
 Cancer Epidemiology Biomarkers and Prevention  
 Cancer Investigation  
 Cancer  
 Cell Reports  
 Lancet Oncology  
 The New England Journal of Medicine  
 Oncologist

### EDITORIAL

Journal of the National Cancer Institute (Associate Editor)  
 Journal of Clinical Oncology (Editorial Board)

### PEER REVIEW PANELS

Member: AVON – International Research Fellowships Award Committee. 2005  
 Member: American Society of Clinical Oncology – Foundation Awards Committee. 2007-11  
 Member: Cancer Research Network (NCI) Pilot Project Program Awards Committee. 2007  
 Member: Hope Foundation / SWOG – Career Development Grant Review Committee. 2007-13  
 Member: California Breast Cancer Research Fund Program Review Committee. 2007  
 Member: NCI CRN Concept Matching Project. 2008  
 Member: Concur Cancer Foundation Grants award program 2008-2011  
 Member: Department of Defense Breast Cancer Program Clinical Protocol Review Panel. 2008-  
 Chair: Susan Komen/ASCO Improving Cancer Care Grant Program. 2009, 2010

Member: ASCO foundation Advanced Clinical Research Award review committee: 2011  
Chair: Concur Cancer Foundation Grants award program 2011-2014  
Chair: ASCO Advanced Clinical Research Award review committee: 2012  
Reviewer: Susan B Komen Research Foundation  
Reviewer: Patient Centered Outcomes Research Institute (PCORI)  
Reviewer: Division Cancer Prevention Control Symptoms Steering Committee  
Reviewer: American Association of Cancer Research Translational Research Award (2011-2013)  
Reviewer: Department of Defense Breast Cancer Research Awards (2013)  
Reviewer: Susan B Komen Research Foundation Awards (2016-2018)  
Reviewer: Rising Tide Foundation (2019)  
Reviewer: NCI Moonshot (Multiple Review Committees (2019-2020)).  
Reviewer: NCI HSOD (2020-2023)  
University of North Carolina Breast SPORE – External Advisory Committee

#### NCI - COMMITTEES/WORKING GROUPS

Coordination Center for Clinical Trials Special Emphasis Panel  
Chair – CIPN Working Group, Symptoms Management Quality of Life Steering Committee  
Member - NCI Concise Informed Consent Template Project.  
Member – NCI Lifestyle Intervention Clinical Trials Planning Committee (2014)  
NCI Breast Cancer Steering Committee (2014-2020)  
NCI Cancer Care Delivery Coordinating Committee (2014-2018)  
NCI Cancer Care Delivery Steering Committee (2014-present)

#### National Committees

SWOG: **Group Co-Chair Elect: SWOG Cancer Research Network (2023-)**  
SWOG: **Vice-Chair: SWOG NCORP Research Base (2014-)**  
SWOG: **Co-Chair: Cancer Care Delivery Committee (2008-)**  
SWOG: **Executive Advisory Committee (2014-)**  
BCRF: **Breast Cancer Research Foundation Scientific Advisory Board (2024-2031)**  
SWOG: Breast Cancer Committee, Survivorship Committee, Symptoms Management Committee  
SWOG: Breast Cancer Translational Research Committee  
ASCO: Publications Committee (2009-2012)  
ASCO: Leadership Development Program (2009)  
ASCO: Health Services Education Committee (2010/11)  
ASCO: Quality of Care Committee (2010-2013)  
ASCO: Education Committee (2010-2013) – Track Leader Health Services  
ASCO: Scientific Review Committee (2012-13)  
AACR: Scientific Review Committee / Prevention (2011-12)  
SABCS: San Antonio Breast Cancer Symposium: Review Committee, Section Chair (2010-2018)  
ASCO: Guidelines Co-Chair – Chemotherapy Induced Peripheral Neuropathy (2015).  
ASCO: Prevention Committee (2013-2015)  
SWOG: Board of Governors  
Hope Foundation: Board of Trustees. (2011-2013)  
Hope Foundation: Vice Chair Board of Trustees (2013-)  
ASCO Workforce Advisory Committee (2013-)  
ASCO Obesity in Cancer Research Summit Working Group (2014, 2016)  
ASCO-ACC Cardio-Oncology Working Group (2014)  
ASCO Quality Care Symposium Faculty (2015-2018)  
ASCO Teams in Oncology Faculty (2016)  
ConcerLinQ: Vice-Chair, Research and Publications (2017-2021)

ASCO: Guidelines Co-Chair – Chemotherapy Induced Peripheral Neuropathy (2019).  
 ASCO Guidelines Co-Chair – Breast Cancer Neoadjuvant Therapy (2018)  
 ASCO Guidelines – Hepatitis B testing in cancer (2019)  
 ASCO/AACR Clinical Trials Training Course – Faculty (2019-2022)  
 ASCO Guidelines – Managing Cancer Pain (2020)  
 ASCO Quality Care Symposium Chair (2018-2021)  
 SWOG Clinical Trials Partnership Executive Committee (2020-present)  
 ISPY PRO/QOL Committee Chair (2020-Present)

#### CANCER CONSORTIUM

2005 – 2012 NY Cancer Consortium -Scientific Advisory Committee, Site PI  
 2010 - 2012 Site PI, NY Phase II Cancer Consortium  
 2004 - MDACC Phase 1 Prevention Consortium

#### **FELLOWSHIP AND GRANT SUPPORT**

---

##### **Current Support:**

2024-2029 Principal Investigator, K12CA279872, CUIMC Calabresi Clinical Oncology Career Development Program. Four scholar training slots per year.

2024-2029 Co-Investigator, R01CA294004, Harnessing digital health and equity informed multi-level implementation strategies to promote uptake of depression treatment in cancer settings: iCan DepCare – PI, Nathalie Moise, \$2,507,954

2023-2026 Site Principal Investigator, BC230531, Early Detection Blood Test for Universal Breast Cancer Screening to Improve Early Diagnosis for Women of all Social and Ethnic Backgrounds – Department of Defense Congressionally Directed Medical Research Program Breast Cancer Research Program, PI, Massimo Cristofanilli (Weill Cornell) \$271,774

2023-2028 Site Principal Investigator, 1R01CA283179, Analyzing Patient-Level Data in a Breast Cancer Clinical Trial – Amrita Basu. \$45,000 per year via subcontract from UCSF.

2023-2026 Principal Investigator and Supplement Lead, 5P50MD017341-03S2, Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (The COMMUNITY Center) – Revision; \$604,300

2023 – 2024 Site Principal Investigator and Project Lead, 2P01CA210961-06A1, The I SPY 2.2 Trial: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes, Core 1 and Project 1. PI – Laura Esserman. \$64,435 yearly subcontract.

2023 - 2024 Advisor, Estee Lauder Companies' Breast Cancer Campaign 30th Anniversary Disparities Initiative, Funding from Breast Cancer Research Foundation, \$16,990 per year.

2024 – 2025 Principal Investigator, Breast Cancer Research Foundation (BCRF) Grant, Interventions to Improve Delivery of Breast Cancer Care; \$225,000

2023 - 2028 Co-Chair, Patient-Centered Outcomes Research Institute (PCORI) Award, Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study; Funding to ASCO \$11,000,000

2023 - 2027 Co-Investigator, R37CA277043, Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy – PI, Dan Hertz (U. Michigan) and Meghna Trivedi (Columbia University); \$5,485 yearly

2023 - 2026 Principal Investigator, R34 DA056796, Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery. \$740,250 total costs

2023 - 2025 Principal Investigator, SAC232153, Intervention to Reduce Food Insecurity in Patients with Metastatic Breast Cancer. \$200,000/year

2022 – 2027 Co-Investigator/Site-PI, R01CA266012-01. Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast Cancer. \$25,239/year

- 2021 - 2026 Principal Investigator (MPI), P50 MD017341-01. Center to improve **C**hronic disease **O**utcomes through **M**ulti-level and **M**ulti-generational approaches **U**nifying **N**ovel **I**nterventions and **T**raining for health equit**Y** or “COMMUNITY”, 2,994,001/year
- 2020-2025 Co-Investigator/Site PI, QLEAPCU22-0222, Biomarkers Consortium – I-SPY TRIAL-2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and MoLecular Analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy. \$99,240 total subcontract.
- 2020 – 2025 Principal Investigator. American Cancer Society Research Professorship. Improving the Quality of Cancer Care. \$400,000. (Flatiron-ACS Supplement \$75,000, Fostering Innovation Award \$100,00)
- 2020 - 2025 Co-Investigator/Site-PI, 1U01CA246648-01A. A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors. \$118,908/year
- 2020 - 2025 Co-Investigator. R01 CA248656-01A1. Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention. \$168,000 (subaward).
- 2017 – 2025 Principal Investigator, Witten Stewardship, Breast Cancer Development Program \$2,000,000 (total)
- 2016 – 2026 Principal Investigator (MPI). T32 CA203703. Oncology Training Program \$320,000/yr
- 2014 – 2025 Co-Investigator, NCI P30. 013696-33, Cancer Center Support Grant: Deputy Director (2023-2025) and Program Leader, Cancer Population Science Program (2014-2025). PI A. Rustgi, \$2,700,000/year
- 2014 – 2025 Principal Investigator (MPI), NCI 1UG1CA189974-01, SWOG NCORP Research Base Central Funding to OHSU \$44,514,865

### **Completed Support:**

- 2023 – 2024 Principal Investigator, Breast Cancer Research Foundation (BCRF) Grant, Interventions to Improve Delivery of Breast Cancer Care; \$225,000
- 2022 - 2025 Co-Investigator, UG1CA189960, Columbia University Minority/Underserved Site NCI Community Oncology Research Program – PI, Dr. Lisa Kachnic and Dr. Jennifer Amengual; \$6,856 yearly
- 2021 – 2025 Co-Investigator, SU2C#6209, DISRUPT: Diversity and Inclusion in Scientific Research Underpinning Prevention and Therapeutic Trials – PI, Nina Bickell (Mount Sinai School of Medicine) and Mary Beth Terry (Columbia University); \$5,485 yearly
- 2020 - 2024 Principal Investigator. Komen Leadership Grant (SAC160066). Medication Reminder Application to Improve Medication Adherence in Women with Breast Cancer. \$600,000
- 2020 - 2023 Co-Investigator. American Cancer Society, Insurance Disparities in Cancer Clinical Trials and the Affordable Care Act, \$25,239/year
- 2021 – 2023 Principal Investigator, Breast Cancer Research Foundation, Interventions to Reduce Therapy Related Adverse Effects, \$200,000
- 2018 – 2023 Co-Investigator, R01 CA226060-01A1. Multicenter trial of decision support for breast cancer chemoprevention. \$446,956
- 2020 - 2022 Principal Investigator, R21 CA242044-01A1. Delays in Acquisition of Oral Antineoplastic. Agents. \$275,000.
- 2018 - 2022 Principal-Investigator, HOPE Foundation, Feasibility of a digital health offering in optimizing opioid pain control regimens in cancer patients, \$100,000.
- 2017 – 2021 Co-Investigator, R01CA214057, Predictors of CVD among breast cancer survivors in an integrated health system, \$16,005/year (Subaward).
- 2015 – 2021 Co-Investigator, PCORI, A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer \$28,665/year (Subaward)
- 2015 – 2020 Principal Investigator, ASCO CER Professorship. Reducing Overuse and Underuse to Improve the Quality and Safety of Breast Cancer Care, \$500,000
- 2018 – 2019 Principal Investigator, Breast Cancer Research Foundation, \$250,000
- 2017 – 2019 Principal Investigator, Avon Foundation for Women Center of Excellence. Center of Excellence. \$750,000
- 2016 - 2019 Principal Investigator, Komen Leadership Grant (SAC160066). Comorbidity, toxicity and breast cancer survival among women on and off clinical trials. \$600,000

- 2013 – 2019 Co-Investigator, NCI R01 CA169121-01A1, The Influence of Hospital Variability on the Management of Cancer-Associated Complications, \$1,998,580.
- 2017 – 2018 Principal Investigator, Improving Quality of Breast Cancer Care, \$250,000.
- 2013 – 2018 Principal Investigator, NCI R01 CA166084-01A1, SWOG-Medicare database to understand late effects of cancer therapy, \$1,519,115.
- 2011 – 2018 Principal Investigator, NIH/NCCAM R01AT00636, Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer, \$2,616,283
- 2016 – 2017 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000.
- 2013- 2017 Co-Investigator, PCORI A Structured Approach to Prioritizing Cancer Research using Stakeholders and Value of Information”
- 2011 – 2017 Principal Investigator, Witten Stewardship, Breast Cancer Development Program \$1,000,000.
- 2014 – 2016 Principal Investigator, NCI R03CA181909-01A1, A randomized trial of topical menthol for chemotherapy induced neuropathy, \$160,00
- 2013 – 2016 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000/annual.
- 2012 – 2016 Principal Investigator, Avon Foundation for Women Center of Excellence. Center of Excellence. \$500,000/year
- 2012 – 2016 Co-Principal Investigator, American Cancer Society – RSG 121247. The Relationship between Insurance and Cancer-Related Prescription Drug Use. (Co-PI, A. Neugut) \$1,250,000.
- 2011 – 2016 Co-Principal Investigator, American Society of Clinical Oncology Quality of Care Grant. Adherence to Hormonal Therapy in Breast Cancer: An Intervention Trial. (Co-PI, A. Neugut) \$1,350,000.
- 2005 – 2016 Co-Principal Investigator, DOD BC043120, Racial disparities in the initiation and intensity of adjuvant therapy for breast cancer, Co-PI A. Neugut, \$9,966,608
- 2008 – 2015 Co-Investigator, Southwest Oncology Group Support Grant, Committee Chair, PI L. Baker
- 2010 – 2014 Co-Investigator, Department of Defense, Racial Disparities in Palliative Care for Prostate Cancer, PI AI Neugut, \$650,000
- 2010 – 2014 Co-Investigator, NCI R01 CA139426, Genome-Wide Predictors of Treatment-related Toxicities, PI C. Ambrisone.
- 2009 – 2014 Co-Investigator, NCI R01CA132931, A Randomized Controlled Trial of Exercise on Aromatase Inhibitor Associated Toxicity, PI M. Irwin. \$ 78,330
- 2012 - 2013 Principal Investigator/Mentor. AHRQ 1R36HS021709-01 Hospital and County-Level Predictors of Immediate Breast Reconstruction Post-Mastectomy. \$42,210
- 2012 – 2013 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000.
- 2011 – 2013 Co-Investigator, NIH/NCI R21CA155973, Feasibility of a weight loss intervention among female cancer survivors in SWOG, PI H. Greenlee, \$406,765
- 2011 - 2013 Principal Investigator. K0MENCU11-1260 Predicting response to neoadjuvant chemotherapy using optical tomographic imaging in women with breast cancer, \$120,000
- 2008 – 2013 Principal Investigator, NCI R01CA134964, Determinants and risks of use and off-label use of expensive oncology drugs. \$1,082,126
- 2007 – 2013 Co-Investigator, NCI R01 CA124924-01, Using Physiological Age to Predict Chemotherapy Toxicity, PI J. Mandelblatt, \$523,200
- 2011 – 2012 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000.
- 2010 – 2012 Co-Investigator, NIH/NCI R21CA152903, Implementing dietary change among Hispanic breast cancer survivors, PI H. Greenlee, \$379,000
- 2010 – 2011 Co-Principal Investigator, Interprogramatic Translational Pilot Award. Adherence to Hormonal Therapy in Breast Cancer: An Intervention Trial. \$75,000
- 2009 – 2011 Co-Investigator, NCI R01 NS055809-01, Dose and treatment selection in clinical trials, PI K. Cheung, \$164,000
- 2008 – 2011 Principal Investigator, NCI S0715, Randomized Placebo Controlled Trial of Acetyl-L-Carnitine For Taxane Induced Neuropathy.

- 2007 – 2011 Principal Investigator, NCI R01 NS055809-01, Phase I/II Randomized, Double-Blinded Placebo-Controlled, Dose-Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer, \$465,000
- 2007 – 2011 Principal Investigator, American Society of Clinical Oncology Advanced Clinical Research Award in Breast Cancer. Taxane-Induced Neuropathy in Breast Cancer Survivors: Incidence, Predictors and Treatment. \$450,000.
- 2007 – 2011 Principal Investigator, The Hope Foundation Development Award. Medicare Claims Data for SWOG Cooperative group trials. \$250,000.
- 2009– 2010 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$240,000.
- 2008 – 2010 Principal Investigator, American Cancer Society RSGT 114106, Adjuvant therapies, variations in care and survival., \$715,000
- 2008 – 2010 Principal Investigator, AstraZenica. Phase II study of Glucosamine with Chondroitin on joint Symptoms Induced by Aromatase Inhibitory in Breast Cancer Patients. \$200,000
- 2007 – 2010 Principal Investigator, Susan Komen Research Award, Posttreatment care of Latina breast cancer survivors, \$298,200
- 2007 – 2010 Co-Investigator (mentor), Gateway Foundation for Cancer Research, Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors, \$177,324
- 2008 – 2009 Co-Principal Investigator, Interprogrammatic Translational Pilot Award. Epigenetic Changes in Peripheral Blood after Adjuvant Chemotherapy for Breast Cancer. \$70,000
- 2008 – 2009 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000.
- 2006 – 2009 Principal Investigator, Irving Scholar Award. Cancer Survivorship Studies \$180,000
- 2006 – 2009 Principal Investigator, Ewig Teaching Award. \$90,000.
- 2005 – 2009 Co-Investigator, American Cancer Society RSGPB- 05-010-01. The effects of chemotherapy and estrogen on cognitive function in premenopausal women with breast cancer. PI F. Tager, \$1,369,145
- 2007 – 2008 Principal Investigator, Breast Cancer Research Foundation. Studies in Cancers Survivorship, \$250,000.
- 2006 – 2008 Co-Investigator (mentor), Lance Armstrong Young Investigator Award, Acupuncture for joint pain induced by aromatase inhibitors, \$109,882.
- 2005 – 2007 Co-Investigator, American Cancer Society RSG - 01-024-04. Effectiveness of Cancer Care in the Elderly, PI A. Neugut, \$778,000.
- 2002 – 2007 Principal Investigator, NCI grant #1-KO7-CA095597. Cancer Survivorship: Osteoporosis Prevention in early stage breast cancer. \$647,975.
- 2001 – 2007 Co-Investigator, Susan Koman of Greater NYC- CRAFT. Enhancing enrolment of minority women in breast cancer clinical trials. PI V. Grann, \$50,000/yr.
- 2001 – 2007 Principal Investigator, Novartis Pharmaceuticals. A randomized, placebo controlled trial of zoledronic acid for the prevention of bone loss in pre-menopausal women with early stage breast cancer \$605,000.
- 2005 – 2006 Principal Investigator, Women at Risk Pilot Grant, Pilot study of the effect of acupuncture for joint pain induced by aromatase inhibitors, \$30,000.
- 2003 – 2006 Principal Investigator, U54 NCI Pilot. Ethnic Neutropenia in Afro-Americans and Afro-Caribbeans. \$495,000.
- 2002 – 2005 Principal Investigator, American Society of Clinical Oncology Career Development Award. Osteoporosis prevention in early stage breast cancer. \$170,000.
- 2003 – 2004 Principal Investigator, Jean Sindab pilot award. Adverse outcome of African American women with breast cancer, \$25,000.
- 2003 – 2004 Principal Investigator, Hope Foundation Junior Investigator Award – Southwest Oncology Group, Adverse outcome of African American women with breast cancer, \$50,000.
- 2002 – 2004 Co-Investigator, NCI RO3-CA96422. Cognitive Effects of Adjuvant Chemotherapy in Women with Breast Cancer. \$160,000.

- 2002 – 2003 Principal Investigator, Avon Products Foundation/American Cancer Society pilot award. Evaluation of cardiotoxicity of trastuzumab and taxane chemotherapy using three-dimensional echocardiographic evaluation of left ventricular chamber and muscle properties. \$70,000.
- 2001 – 2002 Principal Investigator, Sindab Foundation / American Cancer Society Pilot Award. Racial differences in white blood count and platelet count in women with breast cancer. \$50,000.

## NCI NCTN TRIALS

MA27B - Randomized Phase III Trial of Exemestane vs Anastrozole with or without celecoxib in postmenopausal women with receptor positive primary breast cancer – Intergroup Bone Substudy. SWOG Study PI.

SWOG 0307 – A Phase III Randomized, Multicenter Trial Evaluating the Efficacy of Oral Ibandronate versus Intravenous Zoledronate vs Clodronate in women with early stage breast cancer. Bone Sub-Study Co-I.

SWOG S0715 – Randomized Placebo Controlled Trial of Acetyl-L-Carnitine For Taxane Induced Neuropathy. SWOG Study PI.

SWOG S0812 - Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer. SWOG Study Co-I.

SWOG S0927 - A randomized placebo-controlled trial of omega-3-fatty acid for the control of aromatase inhibitor-induced musculoskeletal pain in women with early stage breast cancer. SWOG STUDY PI.

SWOG S1008 - Exercise, Diet, and Counseling in Improving Weight Loss in Overweight Women Who Are Breast or Colorectal Cancer Survivors. SWOG Study Co-I.

NCCTG MA32 - A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer. SWOG Study Co-I.

SWOG S1105 - Randomized Trial of A Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Anastrozole Hormonal Therapy In Women With Early Stage Breast Cancer. SWOG STUDY Co-PI

SWOG S1200 - Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer. SWOG STUDY PI

SWOG S1204 – A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients. SWOG STUDY Co-I

S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." SWOG STUDY Co-I

S1415CD, "TrACER: Pragmatic Trial Assessing CSF prescribing Effectiveness and Risk". SWOG STUDY Co-Pi.

Alliance A011401 (BWEL) "Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer." SWOG STUDY Co-I.

S1703, "Randomized trial comparing overall survival of patients monitored with serum tumor marker directed disease monitoring (STMDDM) versus usual care in patients with metastatic hormone receptor positive breast cancer" SWOG STUDY Co-I

S1711 Decision Support to Increase Chemoprevention Uptake Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ. SWOG STUDY Co-I

S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients. SWOG STUDY CO-I.

S1916: Feasibility of A Digital Medicine Program In Optimizing Opioid Pain Control In Cancer Patients. SWOG STUDY PI

S1912CD A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT): SWOG STUDY Co-I.

SWOG S2013: Immune Checkpoint Inhibitor Toxicity (I-Checkit): A Prospective Observational Study. SWOG STUDY Co-PI.

SWOG S2010: Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Early-Stage Breast Cancer. STUDY Co-PI.

SWOG S2202: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression For The Prevention of Taxane- Induced Peripheral Neuropathy (Stop CIPN). STUDY Co-I.

## **NY PHASE II CANCER CONSORTIUM TRIALS – (Investigator Initiated. Funded by NCI)**

P7868 – A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer. Study Principal Investigator

P6205 – A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination with Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients who Have Progressive Disease After First-Line Endocrine Therapy. Co-Investigator

P5598 – A Phase I/II Trial of Tipifarnib (R115777, Zarnestra™) Plus Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer. Co-Investigator

P7703 – A Phase I/II study of a combination of suberoylanilide hydroxyamic acid (vorinostat) plus paclitaxel and bevacizumab in patients with advanced metastatic and/or local chest wall recurrent breast cancer. Co-Investigator

## **EDUCATIONAL CONTRIBUTIONS**

### Clinical Teaching

Ward Attending, Medical Service, 1 month/year, 2001-.

Oncology Consult Attending, 1-2 months/year, 2001-.

Oncology Outpatient Fellows Clinic, ½ day/week, 2001-7.

Medical Attending, Harkness Report, 1 session/month, 2001-

Pathophysiology Preceptor (Medical School) – Oncology, 2001-

Research Preceptor – Medical School / Residency

Morning Report – 2-4 /Year

### PhD and Masters Research Advisor

John Doyle – PhD Dissertation Committee, Mailman School of Public Health

Elizabeth Kaufman – PhD Dissertation Committee, Mailman School of Public Health

Heather Greenlee - PhD Dissertation Committee, Mailman School of Public Health

Russell McBride – PhD Dissertation Committee, Mailman School of Public Health

Shing Lee – PhD Dissertation Committee, Mailman School of Public Health

Katherine Crew – Masters Thesis Advisor, Mailman School of Public Health

Sujata Narayanan - Masters Thesis Advisor, Mailman School of Public Health

Molly Flaxman – PhD Dissertation Committee, Biomedical Engineering

Joseph Unger – PhD Dissertation Committee, Health Services, University of Washington

Catherine Richards - PhD Dissertation Sponsor, Mailman School of Public Health

Jacquelin Gunther – PhD Dissertation Committee, Mailman School of Public Health

Jenny Cui – MPH (2015), Mentor. Masters Thesis, MSPH

Mirella Alto – PhD Dissertation Committee, Biomedical Engineering

Melissa Beauchemin – PhD Dissertation Committee, Nursing

### Primary Career Development Mentor

Katherine Crew – NCI LRP, POR, KL2, ASCO CDA, ACS Career Development Award

Heather Greenlee – Cancer Treatment Research Foundation, K12; K23; R21

Mathew Maurer – NCI LRP, ASCO YIA, SWOG YIA, K12, Komen Career Catalyst

Olivia Fu – Doris Duke Research Scholar

Kevin Kalinsky – NCI LRP, POR program, KL2

Theresa Shao – ASCO YIA

Karen Adelson – NCI Loan Repayment Program

Emerson Lim – Komen Post-Doc Award; POR program  
Maika Onishi – MD, ASCO Young Investigator Award  
Farah Quyyimi – MD (2016) Mentor, Oncology Fellow, T32  
Ellie Coromilis – MD (2015), Mentor. Medical Student Scholarly Project. Graduation award.  
Shing Lee – American Cancer Society Career Development Award  
Veena Shankaran – ASCO Career Development Award, Coltman Career Development Award  
Joseph Unger – Coltman Career Development Award  
Melissa Accordino, MD - NCI LRP, ASCO YIA, CDA, POR, KL2, SWOG CDA  
Meghna Trivedi, MD – Komen Post-Doc Award, POR, KL2,  
Deborah Keller, MD – KL2  
Daniel O’Neal, MD – Medical Oncology Fellow  
Laura Donovan, MD – Neuro-Oncology Fellow  
Alex Melamed, MD – Gyn-Oncology, KL2  
Jacob Cogen, MD – Medical Oncology Fellow  
Justine Kahn, MD – Pediatric Oncology  
Morgan Lichtenstein, MD – Medical Oncology Fellow  
Melissa Beauchemin, NP, PhD – K-award  
Samantha Mullangi, MD, MBA – ASCO CancerLinq Pilot Award  
Izumi Okado, PhD – F32, K01  
Claire Sathe, MD, JD, Medical Oncology Fellow  
Amrita Basu, PhD - Burroughs Wellcome Fund Innovation in Regulatory Science Award  
Kimberley Lee, MD, MHS -

---

## PUBLICATIONS

1. Liu MA, Raghunathan R, Runcie K, Wang S, Wright JD, Wei AZ, Stein M, **Hershman DL**. Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. JCO Oncol Pract. 2025 Jun 12:OP2500024.
2. Beauchemin MP, Khurana RK, DeStephano D, Valera K, Walker D, Algave M, Kahn JM, Mei B, Chheng HJ, Tolu SS, Sathe C, Rosenberg SM, Benda N, Wright JD, Shelton RC, **Hershman DL**. Implementing Financial Screening for Adolescents and Young Adults Treated in the Outpatient Oncology Setting. JCO Oncol Pract. 2025 Jun 9:OP2400868.
3. Ulene SR, Wang S, Cook JR, McAuley F, Wooster ME, Faheem KF, Varoli A, McGuinness JE, Vasani N, Trivedi MS, Crew KD, Harden E, Law C, **Hershman DL**, Accordino MK. Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer. Breast Cancer Res Treat. 2025 Jun 4.
4. Lee KT, Hu B, Martinez Tyson D, Geiss C, Vadaparampil ST, Jim HSL, Gwede CK, Soliman HH, Henry NL, **Hershman DL**. A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer. Breast Cancer Res Treat. 2025 Jun 3.
5. Bell-Brown A, Tawfik B, Segarra-Vazquez B, Hopkins T, Watabayashi K, O’Kane P, Carlos RC, Langer SL, Unger JM, Darke AK, **Hershman DL**, Ramsey SD, Shankaran V. Addressing Challenges in Research Aimed at Reducing Financial Toxicity Among Cancer Patients and Caregivers: An Example From the CREDIT Study (SWOG S1912CD). Cancer Control. 2025 Jan-Dec;32:10732748251344469.

6. Wooster M, Chen L, Accordino MK, Sathe C, Wright JD, **Hershman DL**. Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer. Breast Cancer Res Treat. 2025 Jul;212(2):217-223.
7. Wright JD, Chen L, Xu X, Hur C, Matsuo K, Elkin EB, **Hershman DL**. Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery. Int J Surg. 2025 Jun 1;111(6):4090-4093.
8. Huang Y, Yoh K, Szamreta EA, Xu X, **Hershman DL**, Wright JD. Patterns of pembrolizumab use for recurrent cervical cancer. Int J Gynecol Cancer. 2025 May;35(5):101802.
9. Gupta A, Till C, Vaidya R, **Hershman DL**, Unger JM. Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials. JAMA Netw Open. 2025 Mar 3;8(3):e250778.
10. Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, Roh JM, Rillamas-Sun E, Lee VS, Kolevska T, Cheng RK, Iribarren C, Nguyen-Huynh M, **Hershman DL**, Kushi LH, Greenlee H. Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors. J Natl Cancer Inst. 2025 Mar 11:djaf063.
11. Huang Y, Kwan ML, Heckbert SR, Smith NL, Othus M, Laurent CA, Roh JM, Rillamas-Sun E, Lee VS, Kolevska T, Cheng RK, Iribarren C, Nguyen-Huynh M, **Hershman DL**, Kushi LH, Greenlee H. Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors. JNCI Cancer Spectr. 2025 Jan 28:pkaf009. doi: 10.1093/jncics/pkaf009. Online ahead of print.
12. Oshry LJ, Lederman RI, Gagnon H, Fikre T, Gundersen DA, Revette AC, Odai-Afotey A, Kantor O, **Hershman DL**, Crew KD, Keating NL, Freedman RA, Ko NY. Racial discrimination among women seeking breast cancer care. NPJ Breast Cancer. 2025 Jan 16;11(1):4.
13. Dibble KE, Rosenberg SM, Snow C, Kirkner GJ, Tayob N, Contreras M, Roma ND, DeGraffinreid CR, Nolan TS, **Hershman DL**, Naughton M, Partridge AH. Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors. BMC Public Health. 2025 Jan 11;25(1):126. doi: 10.1186/s12889-025-21288-4.
14. Vaidya R, Till C, Henry NL, Fisch MJ, **Hershman DL**, Unger JM. Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer. Breast Cancer Res Treat. 2025 Feb;209(3):603-611
15. Unger JM, Till C, Tangen CM, **Hershman DL**, Goodman PJ, LeBlanc M, Barlow WE, Vaidya R, Minasian LM, Parnes HL, Thompson IM Jr. Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. JAMA Oncol. 2024 Nov 7;10(12):1654-62.
16. Ko N, Oshry L, Lederman R, Gagnon H, Fikre T, Gundersen D, Revette A, Odai-Afotey A, Kantor O, **Hershman D**, Crew K, Keating N, Freedman R. See Me, Hear Me: Racial Discrimination Among Women Seeking Breast Cancer Care. NPJ Breast Cancer. 2025 Jn 16;11(1):4.
17. Lichtenstein MRL, Campbell P, Raghunathan R, Beauchemin M, Elkin EB, Crew KD, Accordino M, Ippoliti C, Hwang M, Abramova R, Harden E, Kelly P, Collins N, Faheem K, Wright JD, **Hershman DL**. Pharmacist-Led Video Consultation to Identify and Mitigate Drug Interactions Among Patients Initiating Oral Anticancer Drugs. JCO Oncol Pract. 2024 Sep 30:OP2400326.. Online ahead of print
18. Michel AM, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, Anderson G, Arnold K, Law C, Pruthi S, Sandoval-Leon A, Shirley R, Perdekamp MG, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino DA, Wisinski K, DeYoung CA, Ross M, Floyd J, Kaster A, VanderWalde L, Saphner TJ, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, **Hershman DL**, Neuhouser ML, Arun B, Crew KD, Kukafka R. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-

implementation interviews (SWOG S1904). BMC Med Inform Decis Mak. 2024 Sep 27;24(1):272. doi: 10.1186/s12911-024-02691-0.

19. Kwan ML, Pimentel N, Izano M, Iribarren C, Rana JS, Nguyen-Huynh M, Cheng R, Laurent CA, Lee VS, Roh JM, Rillamas-Sun E, **Hershman DL**, Kushi LH, Greenlee H, Neugebauer R. Adherence to cardiovascular medications and risk of cardiovascular disease in breast cancer patients: A causal inference approach in the Pathways Heart Study. PLoS One. 2024 Sep 19;19(9):e0310531. doi: 10.1371/journal.pone.0310531. eCollection 2024
20. Presant CA, Till C, Vaidya R, Ashing KT, Warren GW, Sun V, Salgia R, Massarelli E, Mortimer JE, Pal S, Dorff T, Amini A, Erhunmwunsee L, Phillips T, **Hershman DL**, Unger JM. Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Cancer. 2025 Jan 1;131(1):e35560.
21. Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, **Hershman DL**, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3737-3747.
22. Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, **Hershman DL**, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Puztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec;30(12):3728-3736.
23. Suzuki Y, Chen L, Matsuo K, Ferris JS, Elkin EB, Melamed A, Kong CY, Bickell N, Myers ER, Havrilesky LJ, Xu X, Blank SV, Hazelton WD, **Hershman DL**, Wright JD. Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer. Gynecol Oncol. 2024 Nov;190:78-83.
24. Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, **Hershman DL**, Basu A. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer. J Am Med Inform Assoc. 2025 Jan 1;32(1):172-180.
25. Sathe C, Raghunathan R, Ulene S, McAuley F, Bhatt KA, McGuinness JE, Trivedi MS, Vasani N, Kalinsky KM, Crew KD, Faheem KF, Harden E, Law C, **Hershman DL**, Accordino MK. Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer. JCO Oncol Pract. 2024 Jul 26:OP2400187.
26. Suzuki Y, Ferris JS, Chen L, Dioun S, Usseglio J, Matsuo K, Xu X, **Hershman DL**, Wright JD. Fertility-preserving Treatment for Stage IA Endometrial Cancer: A Systematic Review and Meta-Analysis. Am J Obstet Gynecol. 2024 Jul 18:S0002-9378(24)00761-0.
27. Bergstein A, Huang Y, **Hershman DL**, Xu X, Wright J. Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis. Gynecol Oncol. 2024 Jul 15;189:49-55.
28. Marin-Chollom AM, Rillamas-Sun E, Koch PA, Contento IR, Gaffney AO, Ulanday KT, **Hershman DL**, Greenlee H. Social Support, Diet, and Physical Activity among Latina/Hispanic Women Breast Cancer Survivors. J Immigr Minor Health. 2024 Jul 2.

29. Diggs A, Huang Y, Melamed A, Szamreta E, Monberg MJ, **Hershman D**, Wright JD. Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer. Int J Gynecol Cancer. 2024 Jul 1;34(7):1001-1010.
30. Swartz JJ, Huang Y, Wu J, Moss H, **Hershman DL**, Wright JD. Incidence of induced abortion among commercially insured pregnant patients with cancer. Contraception. 2024 Oct;138:110511.
31. McGuinness JE, Anderson GL, Mutasa S, **Hershman DL**, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers TB, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser ML, Goodman GE, Brown PH, Ha R, Crew KD. Effects of vitamin D supplementation on a deep learning-based mammographic evaluation in SWOG S0812. JNCI Cancer Spectr. 2024 Jul 1;8(4):pkae042.
32. Rosenberg SM, Zeng C, An A, Ssebyala SN, Stein T, Lombardo G, Walker D, Mercurio AM, Elreda L, Taiwo E, **Hershman DL**, Pinheiro LC. Characterizing "collateral damage" in men and women with metastatic breast cancer (mBC) from diverse racial and ethnic backgrounds in New York City. Breast Cancer Res Treat. 2024 Aug;207(1):129-141.
33. Sathe C, Accordino MK, DeStephano D, Shah M, Wright JD, **Hershman DL**. Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer. Breast Cancer Res Treat. 2024 Aug;206(3):519-526.
34. **Hershman DL**, Vaidya R, Till C, Barlow W, LeBlanc M, Ramsey S, Unger JM. Socioeconomic Deprivation and Health Care Use in Patients Enrolled in SWOG Cancer Clinical Trials JAMA Netw Open. 2024 Mar 4;7(3):e244008.
35. Xiao H, Vaidya R, **Hershman DL**, Unger JM. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 J Clin Oncol. 2024 Jun 1;42(16):1953-1960.
36. Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, **Hershman D**, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336.
37. Huang Y, Rauh-Hain JA, McCoy TH, Hou JY, Hillyer G, Ferris JS, **Hershman D**, Wright JD, Melamed A. Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning Gynecol Oncol. 2024 Jul;186:9-16.
38. Lee KT, Gonzalez BD, Geiss C, Fulton HJ, Charles D, Vadaparampil ST, Henry NL, Jim HSL, **Hershman DL**, Tworoger SS, Gwede CK. Barriers to endocrine therapy adherence: perspectives of Black breast cancer survivors and their providers. J Cancer Surviv. 2024 Mar 23.
39. Pinheiro LC, An A, Zeng C, Walker D, Mercurio AM, **Hershman DL**, Rosenberg SM. Racial and Ethnic Differences in Psychosocial Care Use Among Adults With Metastatic Breast Cancer: A Retrospective Analysis Across Six New York City Health Systems. JCO Oncol Pract. 2024 Mar 11:OP2300528.
40. Chen Y, Markowitz JC, Blanco C, **Hershman DL**, Zhang JT, Hellerstein DJ. Geographical distance predicts psychiatric treatment retention for Hispanic women with comorbid major depression and breast cancer. Breast Cancer Res Treat. 2024 Jun;205(2):249-256.
41. Ferris JS, Suzuki Y, Prest MT, Chen L, Elkin EB, Hur C, **Hershman DL**, Wright JD. Excess morbidity and mortality associated with underuse of estrogen replacement therapy in premenopausal women who undergo surgical menopause. Am J Obstet Gynecol. 2024 Jun;230(6):653.e1-653.e17.
42. Dioun S, Chen L, De Meritens AB, St Clair CM, Hou JY, Khoury-Collado F, Pua T, **Hershman DL**, Wright JD. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecol Oncol. 2024 Mar;182:70-74.
43. Zeng C, Matias-Gomez L, Kelly M, **Hershman DL**, Rosenberg S, Pinheiro LC. Psychosocial support among adults living with metastatic breast cancer: Perspectives from providers across four New York-Presbyterian hospitals. Psychooncology. 2024 Jan;33(1):e6296. doi: 10.1002/pon.6296.

44. Suzuki Y, Ferris JS, Chen L, Dioun S, Usseglio J, Matsuo K, Xu X, **Hershman DL**, Wright JD. Levonorgestrel-releasing intrauterine device therapy versus oral progestin treatment for Reproductive-Aged patients with endometrial intraepithelial neoplasia: a systematic review and Meta-Analysis. J Natl Cancer Inst. 2024 May 8;116(5):653-664.
45. Wolfson JA, Grimes AC, Nuno M, Kerber CL, Ramakrishnan S, Beauchemin M, Dickens D, Levine JM, Roth ME, Scialla M, Woods W, Vargas S, Boayue KB, Chang GJ, Stock W, **Hershman D**, Curran E, Advani A, O'Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncol Pract. 2024 Apr;20(4):491-502.
46. Wen T, Emont J, Huang Y, Matsuo K, **Hershman DL**, Friedman AM, Wright JD. Trends in Cancer-Directed Surgery Rates Associated with the COVID-19 Pandemic. Ann Surg Oncol. 2024 Feb;31(2):731-734. doi: 10.1245/s10434-023-14698-4. Epub 2023 Dec 12.
47. Accordino MK, Lee S, Leu CS, Levin B, Trivedi MS, Crew KD, Kalinsky K, Raghunathan R, Faheem K, Harden E, Taboada A, de Oliveira BD, Larson E, Franks L, Honan E, Law C, **Hershman DL**. Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. Breast Cancer Res Treat. 2024 Feb;204(1):49-59.
48. Xu X, Chen L, Nunez-Smith M, Clark M, Ferris JS, **Hershman DL**, Wright JD. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecol Oncol. 2023 Dec 12;180:118-125.
49. Beauchemin M, Ranjit Raghunathan R, Taboada A, Harden E, Solomon S, **Hershman DL**. A Brief Screening Tool for Assessment of Financial Toxicity. Oncol Nurs Forum. 2023 Dec 13;51(1):17-23. doi: 10.1188/24.ONF.17-23.
50. Kalinowska V, Huang Y, Buckley A, St Clair CM, Pua T, Khoury-Collado F, Hou JY, **Hershman DL**, Wright JD. Hospital Volume and Quality of Care for Emergency Gynecologic Care. Obstet Gynecol. 2024 Feb 1;143(2):303-311.
51. Suzuki Y, Chen L, Ferris JS, St Clair CM, Hou JY, Khoury-Collado F, Pua T, de Meritens AB, Accordino M, **Hershman DL**, Wright JD. Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer. Gynecol Oncol. 2023 Dec 1;180:14-23.
52. Lichtenstein MRL, Beauchemin MP, Raghunathan R, Lee S, Doshi SD, Law C, Accordino MK, Elkin EB, Wright JD, **Hershman DL**. Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs. JCO Oncol Pract. 2024 Jan;20(1):85-92.
53. Yeh C, Zhou M, Bapodra N, **Hershman D**, Espinal E, Moran M, Rivero M, Fojo AT, Bates SE. Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials. Breast Cancer Res Treat. 2024 Feb;204(1):39-47.
54. Kentros PA, Huang Y, Wylie BJ, Khoury-Collado F, Hou JY, de Meritens AB, St Clair CM, **Hershman DL**, Wright JD. Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study. BJOG. 2024 Apr;131(5):690-698.
55. Yabroff KR, Boehm AL, Nogueira LM, Sherman M, Bradley CJ, Shih YT, Keating NL, Gomez SL, Banegas MP, Ambs S, **Hershman DL**, Yu JB, Riaz N, Stockler MR, Chen RC, Franco EL. An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. J Natl Cancer Inst. 2023 Oct 9;115(10):1115-1120.
56. Yabroff KR, Boehm AL, Nogueira LM, Sherman M, Bradley CJ, Shih YT, Keating NL, Gomez SL, Banegas MP, Ambs S, **Hershman DL**, Yu JB, Riaz N, Stockler MR, Chen RC, Franco EL. An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals. JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad063.
57. **Hershman DL**, Bansal A, Barlow WE, Arnold KB, Watabayashi K, Bell-Brown A, Sullivan SD, Lyman GH, Ramsey SD. Intervention Nonadherence in the TrACER (S1415CD) Study: A Pragmatic Randomized Trial of a Standardized Order Entry for CSF Prescribing. JCO Oncol Pract. 2023 Dec;19(12):1160-1167.
58. Lyman GH, Bansal A, Sullivan SD, Arnold KB, Barlow WE, **Hershman DL**, Lad TE, Ramsey SD. Impact of treatment experience on patient knowledge of colony-stimulating factors among patients

receiving cancer chemotherapy: evidence from S1415CD-a large pragmatic trial. Support Care Cancer. 2023 Sep 28;31(10):598.

59. Vaidya R, Unger JM, Loomba R, Hwang JP, Chugh R, Tincopa MA, Arnold KB, **Hershman DL**, Ramsey SD. Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation. Cancer Res Commun. 2023 Sep 28;3(9):1959-1965.
60. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, **Hershman DL**, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. J Clin Oncol. 2023 Dec 10;41(35):5356-5362.
61. Doshi SD, DeStephano D, Accordino MK, Elkin E, Raghunathan RR, Wright JD, **Hershman DL**. Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer. Breast Cancer Res Treat. 2024 Jan;203(1):111-119.
62. Lichtenstein MRL, Levit LA, Schenkel C, Kirkwood K, Fashoyin-Aje LA, Bruinooge SS, Kelley MJ, Mailman JA, Magnuson A, Mirda DP, Natesan D, **Hershman DL**. Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials. Oncologist. 2024 Apr 4;29(4):356-363.
63. Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li FY, Ferrucci LM, Puklin L, Cao A, Nguyen TH, Neuhouser ML, **Hershman DL**, Basen-Engquist K, Jones BA, Knobf T, Chagpar AB, Silber A, Tanasijevic A, Ligibel JA, Irwin ML. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. J Clin Oncol. 2023 Dec 1;41(34):5285-5295.
64. Bell-Brown A, Watabayashi K, Delaney D, Carlos RC, Langer SL, Unger JM, Vaidya RR, Darke AK, **Hershman DL**, Ramsey SD, Shankaran V. Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinics. JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad055.
65. Unger JM, Xiao H, Vaidya R, LeBlanc M, **Hershman DL**. Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials. JAMA Oncol. 2023 Aug 17:e232800.
66. Koch PA, Paul R, Contento IR, Gray HL, Marín-Chollom AM, Santiago-Torres M, Shen H, Jones SMW, **Hershman DL**, Greenlee H. Mi Vida Saludable: Content Validity and Reliability of The Preferences and Self-Efficacy of Diet and Physical Activity Behaviors Questionnaire for Latina Women (PSEDPALW) for Cancer Survivors. Nutrients. 2023 Aug 12;15(16):3563.
67. Wright JD, Chen L, Suzuki Y, Matsuo K, **Hershman DL**. National Estimates of Gender-Affirming Surgery in the US. JAMA Netw Open. 2023 Aug 1;6(8):e2330348.
68. Liu Y, Mullangi S, Debono D, Chen X, Pham T, Fisch MJ, Gordon AS, **Hershman DL**. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors. JCO Oncol Pract. 2023 Sep;19(9):731-740.
69. Kalinowska V, Chen L, Kohn JE, **Hershman DL**, Wright JD. Trends in tubal sterilisation in young women in the United States. BJOG. 2024 Jan;131(1):112-114.
70. Kulkarni A, Chen L, Gockley A, Khoury-Collado F, Hou J, Clair CST, Melamed A, **Hershman DL**, Wright JD. Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals. Gynecol Oncol. 2023 Aug;175:53-59.
71. Rillamas-Sun E, Kwan ML, Iribarren C, Cheng R, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Huang Y, Shen H, **Hershman DL**, Kushi LH, Greenlee H. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug;201(1):117-126. doi: 10.1007/s10549-023-06997-x. Epub 2023 Jun 16.
72. Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, **Hershman DL**. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-

Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 Aug 20;41(24):4004-4013.

73. Odai-Afotey A, Lederman RI, Ko NY, Gagnon H, Fikre T, Gundersen DA, Revette AC, **Hershman DL**, Crew KD, Keating NL, Freedman RA. Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors. Breast Cancer Res Treat. 2023 Jul;200(1):127-137.
74. Markowitz JC, Hellerstein DJ, Falabella G, Lan M, Levenson J, Crew KD, **Hershman DL**. Psychopharmaphobia: Elevated fear of antidepressant medication among patients with major depression and breast cancer. Gen Hosp Psychiatry. 2023 Jul-Aug;83:117-122.
75. Odai-Afotey A, Lederman RI, Ko NY, Gagnon H, Fikre T, Gundersen DA, Revette AC, **Hershman DL**, Crew KD, Keating NL, Freedman RA. Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors. Breast Cancer Res Treat. 2023 Jul;200(1):127-137.
76. Mullangi S, Chen X, Pham T, Liu Y, Gordon AS, Debono D, Fisch MJ, Gönen M, **Hershman DL**. Association of Patient, Physician, and Practice-Level Factors with Uptake of Payer-Led Oncology Clinical Pathways. JAMA Netw Open. 2023 May 1;6(5):e2312461.
77. **Hershman DL**, Chen BE, Sathe C, Parulekar WR, Lemieux J, Ligibel JA, Gelmon KA, Whelan TJ, Goodwin PJ. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). Breast Cancer Res Treat. 2023 Jul;200(1):93-102.
78. Sathe C, Accordino MK, DeStephano D, Shah M, Wright JD, **Hershman DL**. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer. Breast Cancer Res Treat. 2023 Jul;200(1):85-92.
79. Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, **Hershman DL**, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Netw Open. 2023 May 1;6(5):e2311673.
80. Lee SM, Fan W, Wang A, Vaidya R, Redman MW, Gettinger SN, Bazhenova L, Herbst RS, **Hershman DL**, Unger JM. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clin Cancer Inform. 2023 Apr;7:e2200165. doi: 10.1200/CCI.22.00165.
81. Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, **Hershman DL**, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies. Cancer Discov. 2023 Jun 2;13(6):1386-1407.
82. Suzuki Y, Chen L, Hou JY, St Clair CM, Khoury-Collado F, de Meritens AB, Matsuo K, Melamed A, **Hershman DL**, Wright JD. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2023 May 1;141(5):979-987
83. Unger JM, Till C, Hwang JP, Arnold KB, Leblanc M, **Hershman DL**, Ramsey SD. Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. J Natl Cancer Inst. 2023 Jun 8;115(6):703-711.
84. Rillamas-Sun E, Kwan ML, Iribarren C, Cheng R, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Huang Y, Shen H, **Hershman DL**, Kushi LH, Greenlee H. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug;201(1):117-126.

85. Beauchemin MP, DeStephano D, Raghunathan R, Harden E, Accordino M, Hillyer GC, Kahn JM, May BL, Mei B, Rosenblat T, Law C, Elkin EB, Kukafka R, Wright JD, **Hershman DL**. Implementation of Systematic Financial Screening in an Outpatient Breast Oncology Setting. JCO Clin Cancer Inform. 2023 Mar;7:e2200172.
86. Jim HSL, Brady-Nicholls R, **Hershman DL**. The Importance of Patient-Reported Outcomes in Pragmatic Clinical Trials. J Natl Cancer Inst. 2023 Apr 11;115(4):352-354. doi: 10.1093/jnci/djad037.
87. Boone RM, Praiss AM, Huang Y, Melamed A, Khoury-Collado F, Hou JY, Gockley A, St Clair CM, **Hershman DL**, Wright JD. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials. Gynecol Oncol. 2023 Feb;169:70-77.
88. Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, **Hershman DL**, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, Novick KLM, Sedhom R, Seigel C, Stimmel J, Bruera E. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023 Feb 1;41(4):914-930.
89. Liao L, Chen L, Melamed A, **Hershman DL**, Wright JD. Use of Conservative Therapies Before Hysterectomy for Uterine Leiomyomas. Obstet Gynecol. 2023 Feb 1;141(2):371-374.
90. Li AH, Chen L, Melamed A, **Hershman DL**, Wright JD. Medical and surgical retreatment for uterine leiomyoma after myomectomy. BJOG. 2023 Jun;130(7):835-837.
91. Rock MC, Vaidya R, Till C, Unger JM, **Hershman D**, Ramsey S, Nehemiah A, Maeng D, Krouse R. Racial and Ethnic Disparity in Preference-Weighted Quality of Life: Findings from the Selenium and Vitamin E Cancer Prevention Trial. Popul Health Manag. 2023 Jan 10. Online ahead of print.
92. Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Khoury-Collado F, Hur C, Elkin E, Accordino M, **Hershman DL**, Wright JD. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study. BJOG. 2023 Jan;130(2):214-221.
93. Suzuki Y, Huang Y, Ferris J, Kulkarni A, **Hershman D**, Wright JD. Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause. Int J Gynecol Cancer. 2023 Jan 3;33(1):26-34.
94. Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, **Hershman DL**, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer. 2022 Dec 30.
95. Hwang JP, Arnold KB, Unger JM, Chugh R, Tincopa MA, Loomba R, **Hershman D**, Ramsey SD. Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204. Support Care Cancer. 2022 Dec 31;31(1):93.
96. Beauchemin MP, Lichtenstein MRL, Raghunathan R, Doshi SD, Lee S, Law C, Accordino MK, Elkin EB, Wright JD, **Hershman DL**. Impact of a Hospital-Based Specialty Pharmacy in Partnership With a Care Coordination Organization on Time to Delivery and Receipt of Oral Anticancer Drugs. JCO Oncol Pract. 2022 Dec 6:OP2200451.
97. **Hershman DL**, Unger JM, Greenlee H, Capodice J, Lew DL, Darke A, Minasian LM, Fisch MJ, Henry NL, Crew KD. Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial. JAMA Netw Open. 2022 Nov 1;5(11):e2241720.
98. Bell-Brown A, Watabayashi K, Kreizenbeck K, Ramsey SD, Bansal A, Barlow WE, Lyman GH, **Hershman DL**, Mercurio AM, Segarra-Vazquez B, Kurttila F, Myers JS, Golenski JD, Johnson J, Erwin RL, Walia G, Crawford J, Sullivan SD. An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD. J Comp Eff Res. 2022 Dec;11(18):1313-1321.
99. Mullangi S, Aviki EM, **Hershman DL**. Reexamining Social Determinants of Health Data Collection in the COVID-19 Era. JAMA Oncol. 2022 Dec 1;8(12):1736-1738.
100. Ramsey SD, Bansal A, Sullivan SD, Lyman GH, Barlow WE, Arnold KB, Watabayashi K, Bell-Brown A, Kreizenbeck K, Le-Lindqwister NA, Dul CL, Brown-Glaberman UA, Behrens RJ, Vogel V, Alluri N, **Hershman DL**. Effects of a Guideline-Informed Clinical Decision Support System

Intervention to Improve Colony-Stimulating Factor Prescribing: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2022 Oct 3;5(10):e2238191.

101. **Hershman DL**, Bansal A, Sullivan SD, Lyman GH, Barlow WE, Arnold KB, Watabayashi K, Bell-Brown A, Le-Lindqwister N, Dul CL, Brown-Glaberman U, Behrens RJ, Vogel VG, Alluri N, Ramsey SD. A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia. J Clin Oncol. 2023 Jan 20;41(3):590-598.
102. Doshi SD, Lichtenstein MRL, Beauchemin MP, Raghunathan R, Lee S, Law C, Accordino MK, Elkin EB, Wright JD, **Hershman DL**. Factors Associated With Patients Not Receiving Oral Anticancer Drugs. JAMA Netw Open. 2022 Oct 3;5(10):e2236380.
103. Freedman RA, Ko NY, Lederman RI, Gagnon H, Fikre T, Gundersen DA, Revette AC, Odai-Afotey A, Kantor O, **Hershman DL**, Crew KD, Keating NL. Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors. Breast Cancer Res Treat. 2022 Dec;196(3):623-633.
104. Vaidya R, Till C, Greenlee H, **Hershman DL**, Unger JM. Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-Related Cancers, 1986 to 2016. JAMA Netw Open. 2022 Oct 3;5(10):e2234445
105. Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Huang Y, Elkin EB, Melamed A, Wright JD, **Hershman DL**. New and Persistent Sedative-Hypnotic Use after Adjuvant Chemotherapy for Breast Cancer. J Natl Cancer Inst. 2022 Dec 8;114(12):1698-1705.
106. Wright JD, Chen L, Melamed A, Clair CMS, Hou JY, Khoury-Collado F, Gockley A, Accordino M, **Hershman DL**, Xu X. Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation. Obstet Gynecol. 2022 Sep 1;140(3):371-380.
107. Mullangi S, Aviki EM, Chen Y, Robson M, **Hershman DL**. Factors Associated With Cancer Treatment Delay Among Patients Diagnosed With COVID-19. JAMA Netw Open. 2022 Jul 1;5(7).
108. Liao L, Chen L, Gockley A, Melamed A, St Clair CM, Hou JY, Khoury-Collado F, Accordino M, **Hershman DL**, Wright JD. Temporal Trends in Cervical Cancer Screening Practices and Associated Downstream Abnormalities and Procedures Among Women With Insurance in the United States. Obstet Gynecol. 2022 Jul 1;140(1):55-64.
109. Cogan JC, Accordino MK, Beauchemin MP, Spivack JH, Ulene SR, Elkin EB, Melamed A, Taback B, Wright JD, **Hershman DL**. Efficacy of a password-protected, pill-dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. Cancer. 2022 Sep 15;128(18):3392-3399.
110. Tergas AI, Prigerson HG, Shen MJ, Dinicu AI, Neugut AI, Wright JD, **Hershman DL**, Maciejewski PK. Association between immigrant status and advanced cancer patients' location and quality of death. Cancer. 2022 Sep 15;128(18):3352-3359.
111. Cherston C, Yoh K, Huang Y, Melamed A, Gamble CR, Prabhu VS, Li Y, **Hershman DL**, Wright JD. Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer. Gynecol Oncol. 2022 Sep;166(3):552-560.
112. Vikas P, Korde LA, Somerfield MR, **Hershman DL**. Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2022 Sep;18(9):649-651.
113. Diggs A, Sia TY, Huang Y, Gockley A, Melamed A, Khoury-Collado F, St Clair C, Hou JY, **Hershman DL**, Wright JD. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma. Gynecol Oncol. 2022 Aug;166(2):308-316.
114. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, **Hershman DL**, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022 May 24;327(20):1963-1973.
115. Beauchemin MP, Raghunathan RR, Accordino MK, Cogan JC, Kahn JM, Wright JD, **Hershman DL**. New persistent opioid use among adolescents and young adults with sarcoma. Cancer. 2022 Jul 15;128(14):2777-2785.

116. Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE; theMednet.org NCI-CCC Tumor Board Program Collaborative Group, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer. 2022 May 19;8(2)
117. Suzuki Y, Huang Y, Melamed A, Clair CMS, Hou JY, Khoury-Collado F, Gockley A, Accordino M, **Hershman DL**, Wright JD. Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal. Obstet Gynecol. 2022 May 1;139(5):756-763
118. McGuinness JE, Ro V, Mutasa S, Pan S, Hu J, Trivedi MS, Accordino MK, Kalinsky K, **Hershman DL**, Ha RS, Crew KD. Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Res Treat. 2022 Jul;194(1):35-47.
119. Kwan ML, Cheng RK, Iribarren C, Shen H, Laurent CA, Roh JM, **Hershman DL**, Kushi LH, Greenlee H, Rana JS. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022 Jun;193(3):669-675.
120. Korde LA, Somerfield MR, **Hershman DL**; Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline Expert Panel. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022 May 20;40(15):1696-1698
121. Santiago-Torres M, Contento I, Koch P, Tsai WY, Gaffney AO, Marín-Chollom AM, Shi Z, Ulanday KT, Shen H, **Hershman DL**, Greenlee H. Associations Between Acculturation and Weight, Diet Quality, and Physical Activity Among Latina Breast Cancer Survivors: The ¡Mi Vida Saludable! Study. J Acad Nutr Diet. 2022 Sep;122(9):1703-1716.
122. Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, Shi Z, Laurent CA, Lee VS, Roh JM, Santiago-Torres M, Shen H, **Hershman DL**, Kushi LH, Neugebauer R, Kwan ML. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022 May 20;40(15):1647-1658.
123. Watabayashi KK, Bell-Brown A, Kreizenbeck K, Egan K, Lyman GH, **Hershman DL**, Arnold KB, Bansal A, Barlow WE, Sullivan SD, Ramsey SD. Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. BMC Health Serv Res. 2022 Apr 1;22(1):432.
124. Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, Henry NL, Fisch MJ, Lee SM, Blanke CD, **Hershman DL**. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol. 2022 May 1;40(13):1474-1486.
125. Huang Y, Hou JY, Melamed A, St Clair CM, Khoury-Collado F, Gockley A, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer. Gynecol Oncol. 2022 Apr;165(1):160-168.
126. Matsuo K, Chen L, Matsuzaki S, Mandelbaum RS, Ciesielski KM, Silva JP, Klar M, Roman LD, Accordino MK, Melamed A, Elkin E, **Hershman DL**, Wright JD. Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy for Ovarian Cancer Prevention: A Cost-Effectiveness Analysis. Ann Surg. 2022 Jan 27.
127. Wright JD, Huang Y, Li AH, Melamed A, **Hershman DL**. Nationwide Estimates of Annual Inpatient and Outpatient Hysterectomies Performed in the United States. Obstet Gynecol. 2022 Mar 1;139(3):446-448.
128. Kwan ML, Cheng RK, Iribarren C, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Shen H, Rillamas-Sun E, Santiago-Torres M, **Hershman DL**, Kushi LH, Greenlee H. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022 May 20;40(15):1635-1646.
129. Gamble CR, Chen L, Szamreta E, Monberg M, **Hershman D**, Wright J. Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. Arch Gynecol Obstet. 2022 Jun;305(6):1647-1654.

130. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, **Hershman DL**, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff- Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C; COVID-19 and Cancer Consortium (CCC19). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Netw Open. 2022 Jan 4;5(1):e2142046.
131. Shankaran V, Unger JM, Darke AK, Suga JM, Wade JL, Kourlas PJ, Chandana SR, O'Rourke MA, Satti S, Liggett D, **Hershman DL**, Ramsey SD. S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. J Natl Cancer Inst. 2022 Mar 8;114(3):372-380.
132. Kulkarni A, Chen L, Melamed A, **Hershman DL**, Wright JD. Trends in human papillomavirus vaccination among women aged 27 to 45 years, from 2017 to 2019. Am J Obstet Gynecol. 2021 Dec 22:S0002-9378(21)02727-7.
133. Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhaus ML, Crane TE, Frank E, Spears PA, Gillis BP, **Hershman DL**, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, A Carey L, Partridge AH, Ligibel JA. The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. Obesity (Silver Spring). 2022 Jan;30(1):28-38.
134. Wooster M, McGuinness JE, Fenn KM, Singh VM, Franks LE, Lee S, Cieremans D, Lassman AB, **Hershman DL**, Crew KD, Accordino MK, Trivedi MS, Iwamoto F, Welch MR, Haggiagi A, Schultz RD, Huynh L, Sales E, Fisher D, Mayer JA, Kreisl T, Kalinsky K. Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay. Clin Breast Cancer. 2021 Nov 14:S1526-8209(21)00318-9.
135. Zhou ZN, Chen L, Melamed A, St Clair CM, Hou JY, Khoury-Collado F, Gockley A, **Hershman DL**, Wright JD. Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. Gynecol Oncol. 2022 Feb;164(2):341-347.
136. Henry NL, Unger JM, Till C, Crew KD, Fisch MJ, **Hershman DL**. Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms, JNCI Cancer Spectr. 2021 Oct 30;5(6).
137. Dillon J, Chen L, Melamed A, St Clair CM, Hou JY, Khoury-Collado F, Gockley A, Accordino M, **Hershman DL**, Wright JD. Patterns of cervical cancer screening among Medicaid beneficiaries. BJOG. 2022 Jun;129(7):1104-1111.
138. Cham S, Li A, Rauh-Hain JA, Tergas AI, **Hershman DL**, Wright JD, Melamed A. . Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncol. 2022 Jan 1;8(1):159-161.
139. Kluger MD, Huang YY, Kuo JH, Kwon W, Thomas AS, **Hershman DL**, Schrope BA, Sugahara KN, Chabot JA, Wright JD. Perioperative and persistent opioid utilization following pancreatectomy in the United State. HPB (Oxford). 2021 Nov 10:S1365-182X(21)01688-9.
140. Praiss AM, Huang Y, St Clair CM, Melamed A, Khoury-Collado F, Hou JY, Gockley A, Hillyer GC, **Hershman DL**, Wright JD. Long-term outcomes of vaginal hysterectomy for endometrial cancer. Gynecol Oncol. 2022 Jan;164(1):105-112.
141. Marín-Chollom AM, Hale C, Koch P, Gaffney AO, Contento I, Shen H, **Hershman DL**, Brickman AM, Greenlee H.J. Cognitive Functioning and Health in Hispanic/Latina Breast Cancer Survivors. J Immigr Minor Health. 2022 Jun;24(3):597-604.
142. Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Elkin E, Accordino M, **Hershman DL**, Wright JD. Minimally invasive surgery for suspected early-stage ovarian cancer; a cost-effectiveness study. BJOG. 2022 Apr;129(5):777-784.
143. Dioun S, Huang Y, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, **Hershman DL**, Wright JD. Trends in the Use of Minimally Invasive Adnexal Surgery in the United States. Obstet Gynecol. 2021 Nov 1;138(5):738-746
144. Hui D, Darke AK, Guthrie KA, Subbiah IM, Unger JM, **Hershman DL**, Krouse RS, Bakitas M, O'Rourke MA. Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With

- Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncol Pract. 2021 Oct 4:OP2100407.
145. Melamed A, Rauh-Hain JA, Gockley AA, Nitecki R, Ramirez PT, **Hershman DL**, Keating N, Wright JD. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncol. 2021 Sep 30:e214252.
  146. Moss HA, Chen L, **Hershman DL**, Davidson B, Wright JD. Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecol Oncol. 2021 Nov;163(2):262-268.
  147. Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Gelmon KA, Whelan TJ, Ligibel JA, **Hershman DL**, Mayer IA, Hobday TJ, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson AM, Rea DW, Stambolic V. Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectr. 2021 Jul 28;5(5):pkab066.
  148. Santiago-Torres M, Contento I, Koch P, Tsai WY, Brickman AM, Gaffney AO, Thomson CA, Crane TE, Dominguez N, Sepulveda J, Marin-Chollom AM, Paul R, Shi Z, Ulanday KT, Hale C, **Hershman D**, Greenlee H. ¡Mi Vida Saludable! A randomized, controlled, 2 × 2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: Study design and methods. Contemp Clin Trials. 2021 Nov;110:106524.
  149. Unger JM, Beauchemin M, **Hershman DL**. Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. Cancer. 2021 Dec 15;127(24):4574-4584.
  150. Unger JM, Xiao H, LeBlanc M, **Hershman DL**, Blanke CD. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Netw Open. 2021 Jul 1;4(7):e2118433.
  151. Sanft T, Harrigan M, Cartmel B, Ferrucci LM, Li FY, McGowan C, Zupa M, Nguyen TH, Ligibel J, Neuhaus ML, **Hershman DL**, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Irwin ML. Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. Contemp Clin Trials. 2021 Oct;109:106508.
  152. Knisely A, Huang Y, Melamed A, Gockley A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Accordino M, **Hershman DL**, Wright JD. Disparities in Access to High-Volume Surgeons Within High-Volume Hospitals for Hysterectomy. Obstet Gynecol. 2021 Aug 1;138(2):208-217.
  153. Dioun S, Wu J, Chen L, Kaplan S, Huang Y, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Machida H, Mikami M, Matsuo K, **Hershman DL**, Wright JD. Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer: A Meta-analysis. Obstet Gynecol. 2021 Aug 1;138(2):261-271.
  154. Kearney M, Franks L, Lee S, Tiersten A, Makower DF, Cigler T, Mundi P, Chi DC, Goel A, Klein P, Andreopoulou E, Sparano J, Trivedi M, Accordino M, Califano A, **Hershman DL**, Silva J, Kalinsky K. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Res Treat. 2021 Aug;189(1):177-185.
  155. McGuinness JE, Altoe ML, Marone A, Franks LE, Lee SM, Kim HK, Tejada M, Trivedi MS, Accordino MK, Crew KD, **Hershman DL**, Hielscher AH, Kalinsky K. Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. Breast Cancer Res Treat. 2021 Aug;189(1):297-304.
  156. Goodwin PJ, Dowling RJO, Ennis M, Chen BE, Parulekar WR, Shepherd LE, Burnell MJ, Vander Meer R, Molckovsky A, Gurjal A, Gelmon KA, Ligibel JA, **Hershman DL**, Mayer IA, Whelan TJ, Hobday TJ, Rastogi P, Rabaglio-Poretti M, Lemieux J, Thompson AM, Rea DW, Stambolic V. Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. NPJ Breast Cancer. 2021 Jun 8;7(1):74.

157. Cogan JC, Raghunathan RR, Beauchemin MP, Accordino MK, Elkin EB, Melamed A, Wright JD, **Hershman DL**. New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery. *Breast Cancer Res Treat*. 2021 Sep;189(2):445-454.
158. Wright JD, Cogan JC, Huang Y, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Gockley A, Accordino M, Melamed A, **Hershman DL**. Association of New Perioperative Benzodiazepine Use With Persistent Benzodiazepine Use. *JAMA Netw Open*. 2021 Jun 1;4(6):e2112478.
159. Heilbroner SP, Xanthopoulos EP, Buono D, Carrier D, Durkee BY, Corradetti M, Wang TJC, Neugut AI, **Hershman DL**, Cheng SK. Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients. *PLoS One*. 2021 May 27;16(5):e0252053.
160. Cham S, Huang Y, Melamed A, Worley MJ Jr, Hou JY, Tergas AI, Khoury-Collado F, Gockley A, Clair CMST, **Hershman DL**, Wright JD. Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. *Gynecol Oncol*. 2021 May 5:S0090-8258(21)00352-8.
161. Wright JD, Chen L, Tergas AI, Melamed A, St Clair CM, Hou JY, Khoury-Collado F, Gockley A, Accordino M, **Hershman DL**. Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. *JAMA Netw Open*. 2021 Apr 1;4(4):e218373.
162. Beauchemin M, Weng C, Sung L, Pichon A, Abbott M, **Hershman DL**, Schnall R. Data Quality of Chemotherapy-Induced Nausea and Vomiting Documentation. *Appl Clin Inform*. 2021 Mar;12(2):320-328.
163. Hopson MB, Lee S, Accordino M, Trivedi M, Maurer M, Crew KD, **Hershman DL**, Kalinsky K. Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. *Breast Cancer Res Treat*. 2021 Jul;188(2):427-432.
164. Unger JM, Moseley AB, Cheung CK, Osarogiagbon RU, Symington B, Ramsey SD, **Hershman DL**. Persistent disparity: Socioeconomic deprivation and cancer outcomes in patients treated in clinical trial. *J Clin Oncol*. 2021 Apr 20;39(12):1339-1348. PMID: 33729825
165. Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Hur C, **Hershman DL**, Wright JD. Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia. *Obstet Gynecol*. 2021 May 1;137(5):924-934.
166. Sia TY, Huang Y, Gockley A, Melamed A, Khoury-Collado F, St Clair C, Hou JY, Tergas AI, **Hershman DL**, Wright JD. Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. *Gynecol Oncol*. 2021 Jun;161(3):734-740.
167. Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, **Hershman DL**, Ramsey SD. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). *JCO Oncol Pract*. 2021 Nov;17(11):e1821-e1829.
168. Satish T, Raghunathan R, Prigoff JG, Wright JD, Hillyer GA, Trivedi MS, Kalinsky K, Crew KD, **Hershman DL**, Accordino MK. Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. *JCO Oncol Pract*. 2021 Aug;17(8):e1215-e1224.
169. **Hershman DL**, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM. Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors. *J Natl Cancer Inst*. 2021 Aug 2;113(8):989-996.
170. Selter J, Huang Y, Williams SZ, Brady PC, Melamed A, **Hershman DL**, Wright JD. Use of fertility preservation services in male reproductive-aged cancer patients. *Gynecol Oncol Rep*. 2021 Feb 10;36:100716.
171. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang SE, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans F, Yung RL, Harvey BE, **Hershman DL**.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. *J Clin Oncol*. 2021 May 1;39(13):1485-1505.

172. Levit LA, Kaltenbaugh MW, Magnuson A, **Hershman DL**, Goncalves PH, Garrett-Mayer E, Bruinooge SS, Miller RS, Klepin HD. Challenges and opportunities to developing a frailty index using electronic health record data. *J Geriatr Oncol*. 2021 Jun;12(5):851-854.
173. Altoe ML, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino MK, Trivedi MS, **Hershman DL**, Hielscher AH. Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. *Breast Cancer Res*. 2021 Jan 31;23(1):16.
174. Beauchemin M, Dorritie R, **Hershman DL**. Opioid use and misuse in children, adolescents, and young adults with cancer: a systematic review of the literature. *Support Care Cancer*. 2021 Aug;29(8):4521-4527.
175. Altoe M, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino M, Trivedi MS, **Hershman DL**, Hielscher AH. Changes in diffuse-optical-tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes. *Clin Cancer Res*. 2021 Apr 1;27(7):1949-1957.
176. Liang MI, Chen L, **Hershman DL**, Hillyer GC, Huh WK, Guyton A, Wright JD. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. *Gynecol Oncol*. 2020 Dec 27:S0090-8258(20)34218-9.
177. Sedrak MS, Sun CL, **Hershman DL**, Unger JM, Liu J, Dale W, Dizon DS. Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. *JAMA Netw Open*. 2020 Dec 1;3(12):e2031202.
178. Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL 3rd, Fisch MJ, Henry NL, **Hershman DL**, Gralow J. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. *JAMA Oncol*. 2021 Feb 1;7(2):246-254.
179. Knisely A, Zhou ZN, Wu J, Huang Y, Holcomb K, Melamed A, Advincula AP, Lalwani A, Khoury-Collado F, Tergas AI, St Clair CM, Hou JY, **Hershman DL**, D'Alton ME, Huang YY, Wright JD. Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical Procedures. *Ann Surg*. 2021 Jan 1;273(1):34-40.
180. Wu J, Logue T, Kaplan SJ, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, Clair CMS, **Hershman DL**, Wright JD. Less-radical Surgery for Early Stage Cervical Cancer: A Systematic Review. *Am J Obstet Gynecol*. 2021 Apr;224(4):348-358.e5.
181. Tobias CJ, Chen L, Melamed A, St Clair C, Khoury-Collado F, Tergas AI, Hou JY, Hur C, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. *JAMA Netw Open*. 2020 Dec 1;3(12):e2028612.
182. Nghiem VT, Vaidya R, Lyman GH, **Hershman DL**, Ramsey SD, Unger JM. Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials. *Value Health*. 2020 Dec;23(12):1653-1661.
183. Unger JM, **Hershman DL**, Till C, Minasian LM, Osarogiagbon RU, Fleury ME, Vaidya R. "When offered to participate:" A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. *J Natl Cancer Inst*. 2021 Mar 1;113(3):244-257.
184. Praiss AM, Huang Y, St Clair CM, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, Hu J, Hur C, **Hershman DL**, Wright JD. Using machine learning to create prognostic systems for endometrial cancer. *Gynecol Oncol*. 2020 Dec;159(3):744-750.
185. Chen LC, Huang Y, Hou JY, Khoury-Collado F, Melamed A, St Clair CM, Tergas AI, Hur C, Hillyer GC, **Hershman DL**, Wright JD. Toxicity after adjuvant therapy for stage III uterine cancer. *Gynecol Oncol*. 2020 Dec;159(3):737-743.

186. Knisely AT, St Clair CM, Hou JY, Collado FK, **Hershman DL**, Wright JD, Melamed A. Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. JAMA Netw Open. 2020 Sep 1;3(9).
187. Knisely A, Wu J, Kaplan SJ, Zhou ZN, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Huang YY, **Hershman DL**, Wright JD. Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. Cancer Invest. 2020 Sep;38(8-9):436-444.
188. Blanco M, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Cost of care for the initial management of cervical cancer in women with commercial insurance. Am J Obstet Gynecol. 2020 Aug 17:S0002-9378(20)30867.
189. Wu J, Huang Y, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, St Clair CM, Ananth CV, **Hershman DL**, Wright JD. The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. Gynecol Oncol. 2020 Nov;159(2):309-316.
190. Syeda SK, Chen L, Hou JY, Tergas AI, Khoury-Collado F, Melamed A, St Clair CM, Accordino MK, Neugut AI, **Hershman DL**, Wright JD. Trends in venous thromboembolism prophylaxis in gynecologic surgery for benign and malignant indications. Arch Gynecol Obstet. 2020 Oct;302(4):935-945.
191. Huang Y, Jacobson JS, Tergas AI, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Insurance-Associated Disparities in Opioid Use and Misuse Among Patients Undergoing Gynecologic Surgery for Benign Indications. Obstet Gynecol. 2020 Sep;136(3):565-575.
192. Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, **Hershman DL**, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol. 2020 Nov 1;38(31):3698-3715.
193. Loprinzi CL, Lachetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, **Hershman DL**. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1;38(28):3325-3348.
194. Wong SF, Unger JM, Wade JL 3rd, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR Jr, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, **Hershman DL**, Moinpour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020 Jul 8;4(1):54.
195. Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, **Hershman DL**, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707.
196. Accordino MK, Wright JD, Buono D, Lin A, Huang Y, Neugut AI, Hillyer GC, **Hershman DL**. Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data. Breast Cancer Res Treat. 2020 Aug;183(1):201-211.
197. Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, **Hershman D**, Connolly E, Saenger Y, Kalinsky K. Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Front Oncol. 2020 Jun 16;10:968
198. Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, **Hershman DL**, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, Rea D, Rabaglio M, Ellard S, Mates M, Bedard P, Pitre L, Vandenberg T, Jo Dowling R, Parulekar W, Goodwin PJ. The effect of metformin vs placebo on sex hormones in CCTG MA.32. J Natl Cancer Inst. 2021 Feb 1;113(2):192-198.

199. Unger JM, Blanke CD, LeBlanc M, **Hershman DL**. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. *JAMA Netw Open*. 2020 Jun 1;3(6):e2010651.
200. Shankaran V, Unger JM, Darke AK, **Hershman DL**, Ramsey SD. Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. *Contemp Clin Trials*. 2020 Aug;95:106037.
201. Knisely A, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. *Gynecol Oncol*. 2020 Aug;158(2):415-423.
202. **Hershman, DL**, Unger, JM, Hillyer, GC, Moseley, A, Arnold, KB, Dakhil, SR, Esparaz, BT, Kuan, MC, Graham, ML, Lackowski, DM, Edenfield, WJ, Dayao, ZR, Henry, NL, Gralow, JR, Ramsey, SDD<sup>3</sup>, Neugut, AI. Randomized Trial of Text-Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer: SWOG S1105 *J Clin Oncol*. 2020 Jul 1;38(19):2122-2129.
203. Kalinsky K, Accordino MK, Hosi K, Hawley JE, Trivedi MS, Crew KD, **Hershman DL**. Characteristics and Outcomes of Patients With Breast Cancer Diagnosed With SARS-Cov-2 Infection at an Academic Center in New York City. *Breast Cancer Res Treat*. 2020 Jul;182(1):239-242.
204. **Hershman DL**, Till C, Wright JD, Accordino M, Vaidya R, Barlow WE, Ramsey S, Unger JM. Healthcare Utilization and Cost of Care in Elderly Breast Cancer Patients Enrolled in SWOG Clinical Trials. *Breast Cancer Res Treat*. 2020 Jun;181(2):455-463.
205. Cannioto RA, Hutson A, Dighe S, McCann W, McCann SE, Zirpoli GR, Barlow W, Kelly KM, DeNysschen CA, **Hershman DL**, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Physical Activity Before, During and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. *J Natl Cancer Inst*. 2021 Jan 4;113(1):54-63.
206. Unger JM, Blanke CD, LeBlanc M, Barlow WE, Vaidya R, Ramsey SD, **Hershman DL**. Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. *JAMA Netw Open*. 2020 Apr 1;3(4):e203842.
207. Huang AB, Huang Y, Hur C, Tergas AI, Khoury-Collado F, Melamed A, St Clair CM, Hou JY, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Impact of Quality of Care on Racial Disparities in Survival for Endometrial Cancer. *Am J Obstet Gynecol*. 2020 Sep;223(3):396.e1-396.e13.
208. Praiss AM, Huang Y, St Clair CM, Tergas AI, Melamed A, Khoury-Collado F, Hou JY, Hur C, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. A Modern Assessment of the Surgical Pathologic Spread and Nodal Dissemination of Endometrial Cancer. *Gynecol Oncol*. 2020 May;157(2):329-334.
209. Lauren B, Ostvar S, Silver E, Ingram M, Oh A, Kumble L, Laszkowska M, Chu JN, **Hershman DL**, Manji G, Neugut AI, Hur C. Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. *J Oncol*. 2020 Feb 17;2020:2198960.
210. Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, **Hershman DL**, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. *Cancer Chemother Pharmacol*. 2020 Apr;85(4):741-751.
211. Hillyer GC, Beauchemin M, **Hershman DL**, Kelsen M, Brogan FL, Sandoval R, Schmitt KM, Reyes A, Terry MB, Lassman AB, Schwartz GK. Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients. *Clin Trials*. 2020 Apr;17(2):184-194.
212. Beauchemin M, Sung L, **Hershman DL**, Weng C, Dupuis LL, Schnall R. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. *Support Care Cancer*. 2020 Oct;28(10):4761-4769.

213. Kuo JH, Huang Y, Kluger MD, **Hershman DL**, Chabot JA, Lee JA, Wright JD. Use and Misuse of Opioids After Endocrine Surgery Operations. Ann Surg. 2021 Dec 1;274(6):e1144-e1152.
214. Hopson MB, Onishi M, Awad D, Buono D, Maurer M, Crew KD, Shane E, **Hershman DL**, Kalinsky K. Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Clin Breast Cancer. 2020 Jun;20(3):e327-e333.
215. **Hershman DL**, Accordino MK, Shen S, Buono D, Crew KD, Kalinsky K, Trivedi MS, Hur C, Hu J, Unger JM, Wright JD. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 2020. Apr 1;126(7):1541-1549
216. Kronish IM, Cheung YK, Julian J, Parsons F, Lee J, Yoon S, Valdimarsdottir H, Green P, Suls J, **Hershman DL**, Davidson KW. Clinical Usefulness of Bright White Light Therapy for Depressive Symptoms in Cancer Survivors: Results from a Series of Personalized (N-of-1) Trials. Healthcare (Basel). 2019 Dec 30;8(1):10.
217. Ambrosone CB, Zirpoli GR, Hutson AD, McCann WE, McCann SE, Barlow WE, Kelly KM, Cannioto R, Sucheston-Campbell LE, **Hershman DL**, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Galow JR, Budd GT, Albain KS. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2020 Mar 10;38(8):804-814.
218. Youngerman BE, Joiner EF, Wang X, Yang J, Welch MR, McKhann GM 2nd, Wright JD, **Hershman DL**, Neugut AI, Bruce JN. Patterns of seizure prophylaxis after oncologic neurosurgery. J Neurooncol. 2020 Jan;146(1):171-180.
219. Kronish IM, Fenn K, Cohen L, **Hershman DL**, Green P, Jenny Lee SA, Suls J. Extent of Exclusions for Chronic Conditions in Breast Cancer Trials. JNCI Cancer Spectr. 2018 Dec 11;2(4):pky059.
220. Sia TY, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Trends in Use and Effect on Survival of Simple Hysterectomy for Early-Stage Cervical Cancer. Obstet Gynecol. 2019 Dec;134(6):1132-1143.
221. Galow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, **Hershman DL**, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707.
222. Unger JM, Nghiem VT, **Hershman DL**, Vaidya R, LeBlanc M, Blanke CD. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Netw Open. 2019 Sep 4;2(9):e1910593.
223. Gamble CR, Huang Y, Tergas AI, Khoury-Collado F, Hou JY, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals. JNCI Cancer Spectr. 2019 Jun 7;3(3):pkz039.
224. Fenn K, Maurer M, Lee SM, Crew KD, Trivedi MS, Accordino MK, **Hershman DL**, Kalinsky K. Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. Clin Breast Cancer. 2020 Feb;20(1):80-86.
225. Schlechtweg K, Chen L, St Clair CM, Tergas AI, Khoury-Collado F, Hou JY, Melamed A, Neugut AI, **Hershman DL**, Wright JD. Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. Gynecol Oncol. 2019 Nov;155(2):254-261.
226. Altoe ML, Marone A, Kim HK, Kalinsky K, **Hershman DL**, Hielscher AH, Ha RS. Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomed Opt Express. 2019 Aug 1;10(8):4305-4315.
227. Beauchemin M, Murray MT, Sung L, **Hershman DL**, Weng C, Schnall R. Clinical decision support for therapeutic decision-making in cancer: A systematic review. Int J Med Inform. 2019 Oct;130:103940

228. Lee SM, Miao J, Wu R, Unger JM, Cheung K, **Hershman DL**. A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. Health Qual Life Outcomes. 2019 Aug 22;17(1):146.
229. Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, **Hershman DL**, Meyskens FL Jr, Taylor L, Blanke CD. Trends in Medical Aid in Dying in Oregon and Washington. JAMA Netw Open. 2019 Aug 2;2(8).
230. Latham AH, Chen L, Hou JY, Tergas AI, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. Gynecol Oncol. 2019 Oct;155(1):13-20.
231. Barzi A, **Hershman DL**, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM. Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. Arch Osteoporos. 2019 Jul 28;14(1):83.
232. Knisely A, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Effect of regionalization of endometrial cancer care on site of care and patient travel. Am J Obstet Gynecol. 2020 Jan;222(1):58.e1-58.e10.
233. Wright JD, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, **Hershman DL**. Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstet Gynecol. 2019 Aug;134(2):250-26.
234. Quyyumi FF, Wright JD, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, **Hershman DL**. Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. Cancer Invest. 2019;37(6):233-24.
235. Raab GT, Lin A, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Buono DL, Hur C, Kiran RP, Wright JD, **Hershman DL**, Neugut AI. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019 Sep;18(3):e294- e.
236. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019 Jul;134(1):49-57.
237. Syeda S, Chen L, Hou JY, Tergas AI, Khoury-Collado F, Melamed A, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer. Obstet Gynecol. 2019 Jul;134(1):17-29.
238. Wright JD, Chen L, Buskwofie A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Hur C, Neugut AI, **Hershman DL**. Regionalization of care for women with ovarian cancer. Gynecol Oncol. 2019 Aug;154(2):394-400.
239. Crew KD, Anderson GL, **Hershman DL**, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhaus M, Goodman GE, Brown PH. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila). 2019 Jul;12(7):481-490.
240. Quyyumi FF, Wright JD, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, **Hershman DL**. Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. Cancer Invest. 2019;37(6):233-241.
241. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019 Jul;134(1):49-57.
242. Syeda S, Chen L, Hou JY, Tergas AI, Khoury-Collado F, Melamed A, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer. Obstet Gynecol. 2019 Jul;134(1):17-29.

243. Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL 3rd, **Hershman DL**. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. Cancer. 2019 Jun 15;125(12):2123-2129.
244. Raab GT, Lin A, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Buono DL, Hur C, Kiran RP, Wright JD, **Hershman DL**, Neugut AI. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019 Sep;18(3):e294-e299.
245. Wright JD, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, **Hershman DL**. Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer. Obstet Gynecol. 2019 Jun;133(6):1109-1119..
246. Wright JD, Chen L, Buskwofie A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Hur C, Neugut AI, **Hershman DL**. Regionalization of care for women with ovarian cancer. Gynecol Oncol. 2019 Aug;154(2):394-400.
247. Baglia ML, Lin IH, Cartmel B, Sanft T, Ligibel J, **Hershman DL**, Harrigan M, Ferrucci LM, Li FY, Irwin ML. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. 2019 Jul 1;125(13):2262-2271.
248. Unger JM, Vaidya R, **Hershman DL**, Minasian LM, Fleury ME. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. J Natl Cancer Inst. 2019 Mar 1;111(3):245-255.
249. Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, **Hershman DL**, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform. 2019 Mar;3:1-12
250. Heilbroner SP, Xanthopoulos EP, Buono D, Huang Y, Carrier D, Shah A, Kim J, Corradetti M, Wright JD, Neugut AI, **Hershman DL**, Cheng SK. Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer. Lung Cancer. 2019 Mar;129:8-15.
251. Cham S, Chen L, St Clair CM, Hou JY, Tergas AI, Melamed A, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Development and Validation of a Risk-Calculator for Adverse Perioperative Outcomes for Women with Ovarian Cancer. Am J Obstet Gynecol. 2019 Jun;220(6):571.e1-571.
252. Selter J, Huang Y, Grossman Becht LC, Palmerola KL, Williams SZ, Forman E, Ananth CV, Hur C, Neugut AI, **Hershman DL**, Wright JD. Use of Fertility Preservation Services in Female Reproductive-Aged Cancer Patients. Am J Obstet Gynecol. 2019 Oct;221(4):328.e1-328.e16.
253. Praiss AM, Chen L, St Clair CM, Tergas AI, Khoury-Collado F, Hou JY, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Safety of same-day discharge for minimally invasive hysterectomy for endometrial cancer. Am J Obstet Gynecol. 2019 Sep;221(3):239.e1-239.e11.
254. Jones NL, Huang Y, Chatterjee S, Tergas AI, Burke WM, Hou JY, Deutsch I, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Patterns of care and outcomes for women with uterine cancer and ovarian metastases. Int J Gynecol Cancer. 2019 Feb;29(2):365-376.
255. Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O'Neil DS, Accordino MK, Kiran RP, Wright J, **Hershman DL**. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clin Colorectal Cancer. 2019 Jun;18(2):133-140.
256. Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, **Hershman DL**, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC. NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019 Jun1:111(6):531-537.
257. Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, **Hershman DL**.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019 Apr 1;5(4):497-505.

258. Unger JM, **Hershman DL**, Fleury ME, Vaidya R. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol. 2019 Mar 1;5(3):326-333.
259. Chin C, Consul N, Jadeja P, Kwak E, Patel S, Wynn R, **Hershman D**, Connolly EP, Ha R. Utility of preoperative breast MRI in patient selection for accelerated partial breast irradiation by different consensus guidelines. Breast J. 2019 Jan;25(1):160-162.
260. Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, Accordino MK, Wright JD, **Hershman DL**, Lentzsch S, Neugut AI. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma. J Natl Compr Canc Netw. 2019 Jan;17(1):22-28.
261. Quyyumi FF, Wright JD, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, **Hershman DL**. Factors Associated With Follow-Up Care Among Women With Early-Stage Breast Cancer. J Oncol Pract. 2019 Jan;15(1):e1-e9
262. Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA, **Hershman DL**, Dannenberg AJ, Iyengar NM. Obesity-associated breast inflammation among Hispanic/Latina breast cancer patients. Cancer Prev Res (Phila). 2019 Jan;12(1):21-30.
263. Blanco C, Markowitz JC, Hellerstein DJ, Nezu AM, Wall M, Olsson M, Chen Y, Levenson J, Onishi M, Varona C, Okuda M, **Hershman DL**. A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer. Breast Cancer Res Treat. 2019 Jan;173(2):353-364.
264. Wright JD, Chen L, Accordino M, Taback B, Ananth CV, Neugut AI, **Hershman DL**. Regional Market Competition and the Use of Immediate Breast Reconstruction After Mastectomy. Ann Surg Oncol. 2019 Jan;26(1):62-70.
265. Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Effect of Minimum-Volume Standards on Patient Outcomes and Surgical Practice Patterns for Hysterectomy. Obstet Gynecol. 2018 Nov;132(5):1229-1237.
266. Greenlee H, Lew DL, **Hershman DL**, Newman VA, Hansen L, Hartman SJ, Korner J, Shi Z, Sardo Molmenti CL, Sayegh A, Fehrenbacher L, Lo S, Klemp J, Rinn K, Robertson JM, Unger J, Gralow J, Albain K, Krouse R, Fabian C. Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Obesity 2018 Oct;26(10):1539-1549.
267. Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, **Hershman DL**, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA. National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. J Clin Oncol. 2018 Nov 10;36(32):3259-3268.
268. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, **Hershman DL**. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Res Treat. 2018 Dec;172(3):603-610.
269. **Hershman DL**, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisler WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):167-176.
270. Nieto VL, Huang Y, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Use and Outcomes of Minimally Invasive Hysterectomy for Women with Non-Endometrioid Endometrial Cancers. Am J Obstet Gynecol. 2018 Nov;219(5):463.e1-463.e12.

271. Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, **Hershman DL**, Baker L, Ramsey SD. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Med. 2018 Sep;7(9):4251-4260.
272. Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, **Hershman DL**. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiol. 2018 Aug;55:117-122.
273. Wright JD, Ruiz MP, Chen L, Gabor LR, Tergas AI, St Clair CM, Hou JY, Ananth CV, Neugut AI, **Hershman DL**. Changes in Surgical Volume and Outcomes Over Time for Women Undergoing Hysterectomy for Endometrial Cancer. Obstet Gynecol. 2018 Jul;132(1):59-69.
274. Selter J, Grossman Becht LC, Huang Y, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. Am J Obstet Gynecol. 2018 Oct;219(4):415-417.
275. Accordino MK, Wright JD, Vasan S, Buono DL, Hu JC, Neugut AI, **Hershman DL**. Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia. JAMA Oncol. 2018 Jul 1;4(7):996-998.
276. Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Characteristics Associated with Prolonged Length of Stay after Hysterectomy for Benign Gynecologic Conditions. Am J Obstet Gynecol. 2018 Jul;219(1):89.
277. Cui RR, Chen L, Tergas AI, Hou JY, St Clair CM, Neugut AI, Ananth CV, **Hershman DL**, Wright JD. Trends in Use and Survival Associated With Fertility-Sparing Trachelectomy for Young Women With Early-Stage Cervical Cancer. Obstet Gynecol. 2018 Jun;131(6):1085-1094.
278. Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Outcomes of Hysterectomy Performed by Very Low-Volume Surgeons. Obstet Gynecol. 2018 Jun;131(6):981-990.
279. Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, **Hershman DL**. Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clin Transl Oncol. 2018 Nov;20(11):1474-1483.
280. Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, **Hershman DL**, Blanke CD, Ramsey SD. A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies. J Natl Cancer Inst. 2018 Jun 1;110(6):553-559.
281. Kroenke CH, **Hershman DL**, Gomez SL, Adams SR, Eldridge EH, Kwan ML, Ergas IJ, Kubo A, Kushi LH. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug;170(3):623-631.
282. **Hershman DL**, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, Unger JM. Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. J Clin Oncol. 2018 Sep 10;36(26):2710-2717.
283. Gómez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, **Hershman DL**, Wright JD. Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma. Cancer Invest. 2018 Mar 16;36(3):190-198.
284. Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, **Hershman DL**, Wright JD. Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. Gynecol Oncol. 2018 Jun;149(3):545-553.
285. Zirpoli GR, McCann SE, Sucheston-Campbell LE, **Hershman DL**, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain

- KS, Ambrosone CB. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study. *J Natl Cancer Inst.* 2017 Dec 1;109(12):dix098.
286. Unger JM, **Hershman DL**, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr.. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst.* 2018 Nov 1;110(11):1208-1215.
287. Buskwofie A, Huang Y, Tergas AI, Hou JY, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Impact of hospital volume on racial disparities and outcomes for endometrial cancer. *Gynecol Oncol.* 2018 May;149(2):329-336.
288. Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, **Hershman DL**, Hielscher AH. Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. *Radiology.* 2018 Feb 12:161041.
289. Leng S, Lentzsch S, Shen Y, Tsai WY, Wright JD, **Hershman DL**, Neugut AI. Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. *Leuk Lymphoma.* 2018 Feb 2:1-5.
290. Chavez-MacGregor M, Unger JM, Moseley A, Ramsey SD, **Hershman DL**. Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. *Cancer.* 2018 Apr 15;124(8):1760-1769.
291. **Hershman DL**, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). *J Natl Cancer Inst.* 2018 Jun 1;110(6):669-676.
292. Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Racial disparities in young women with endometrial cancer. *Gynecol Oncol.* 2018 Mar;148(3):527-534.
293. Freedman RA, Revette AC, **Hershman DL**, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL. Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. *Biores Open Access.* 2017 Dec 1;6(1):159-168.
294. Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, **Hershman D**, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. *Pharmacogenet Genomics.* 2018 Feb;28(2):49-55.
295. Richards CA, Rundle AG, Wright JD, **Hershman DL**. Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. *JAMA Surg.* 2018 Apr 1;153(4):344-351.
296. Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. *Gynecol Oncol.* 2018 Jan;148(1):19-27.
297. Youngerman BE, Neugut AI, Yang J, **Hershman DL**, Wright JD, Bruce JN. The modified frailty index and 30-day adverse events in oncologic neurosurgery. *J Neurooncol.* 2018 Jan;136(1):197-206.
298. Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, **Hershman DL**, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. *J Clin Oncol.* 2018 Feb 1;36(4):326-332
299. Bercow AS, Chen L, Chatterjee S, Tergas AI, Hou JY, Burke WM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Cost of Care for the Initial Management of Ovarian Cancer. *Obstet Gynecol.* 2017 Dec;130(6):1269-1275.

300. Lee SM, **Hershman DL**, Miao J, Zhong X, Unger JM, Cheung YKK. Estimating global treatment toxicity burden from adverse-event data. Cancer. 2018 Feb 15;124(4):858-864.
301. Ligibel JA, Alfano CM, **Hershman DL**, Merrill JK, Basen-Engquist K, Bloomgarden ZT, Demark-Wahnefried W, Dixon S, Hassink SG, Jakicic JM, Morton JM, Okwuosa TM, Powell-Wiley TM, Rothberg AE, Stephens M, Streett SE, Wild RA, Westman EA, Williams RJ, Wollins DS, Hudis CA. American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S34-S39
302. Malone H, Cloney M, Yang J, **Hershman DL**, Wright JD, Neugut AI, Bruce JN. Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. Neurosurgery. 2018 Aug 1;83(2):263-269
303. Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery. Int J Gynecol Cancer. 2018 Jan;28(1):19-25
304. Ligibel JA, Barry WT, Alfano C, **Hershman DL**, Irwin M, Neuhaus M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017 Sep 21;3:37.
305. Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. All-Cause Mortality in Young Women with Endometrial Cancer Receiving Progesterone Therapy. Am J Obstet Gynecol. 2017 Dec;217(6):669.e1-669.
306. Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, **Hershman DL**. Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. Obstet Gynecol. 2017 Sep;130(3):545-553.
307. Accordino MK, Wright JD, Vasan S, Neugut AI, Gross T, Hillyer GC, **Hershman DL**. Association between survival time with metastatic breast cancer and aggressive end-of-life care. Breast Cancer Res Treat. 2017 Nov;166(2):549-558.
308. Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, **Hershman DL**, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. NPJ Breast Cancer. 2016 Dec 14;2:16037.
309. Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, **Hershman DL**, Goodman GE, Brown PH, Meyskens FL, Albain KS. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. NPJ Breast Cancer. 2016 Aug 10;2:16024.
310. Margolis B, Chen L, Accordino MK, Hillyer GC, Hou JY, Tergas AI, Burke WM, Neugut AI, Ananth CV, **Hershman DL**, Wright JD. Trends in end-of-life care and health care spending in women with uterine cancer. Am J Obstet Gynecol. 2017 Jul 1. (17)30848-7.
311. Lee SM, Zhang Y, Minasian LM, Unger JM, **Hershman DL**. Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib. Cancer Invest. 2017 Aug 9;35(7):484-489.
312. Bansal A, Sullivan SD, **Hershman DL**, Lyman GH, Barlow WE, McCune JS, Ramsey SD. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. J Comp Eff Res. 2017 Jul;6(5):461-470.

313. Govindappagari S, Friedman AM, Chen L, Ananth CV, D'Alton ME, **Hershman DL**, Wright JD. Using publicly reported hospital data to predict obstetric quality. J Matern Fetal Neonatal Med. 2017 Aug;30(16):1984-1991.
314. Wright JD, Desai VB, Chen L, Burke WM, Tergas AI, Hou JY, Accordino M, Ananth CV, Neugut AI, **Hershman DL**. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12.
315. Wright JD, Chen L, Gabor L, Burke WM, Tergas AI, Hou JY, Ananth CV, Neugut AI, **Hershman DL**. Patterns of Specialty-Based Referral and Perioperative Outcomes for Women With Endometrial Cancer Undergoing Hysterectomy. Obstet Gynecol. 2017 Jul;130(1):81-90.
316. Wright JD, Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Desai V, Hu JC, Ananth CV, Neugut AI, **Hershman DL**. Utilization of sentinel lymph node biopsy for uterine cancer. Am J Obstet Gynecol. 2017 Jun;216(6):594.
317. Crew KD, Albain KS, **Hershman DL**, Unger JM, Lo SS. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer. 2017 May 19;3:20.
318. Kwan ML, Roh JM, Laurent CA, Lee J, Tang L, **Hershman D**, Kushi LH, Yao S. Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun;28(6):557-562.
319. Blanke C, LeBlanc M, **Hershman D**, Ellis L, Meyskens F. Characterizing 18 Years of the Death With Dignity Act in Oregon. JAMA Oncol. 2017 Oct 1;3(10):1403-1406.
320. Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol. 2017 May;145(2):269-276.
321. Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, **Hershman DL**, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ; From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Res Treat. 2017 Jul;164(2):371-378.
322. Bian J, Chen B, **Hershman DL**, Marks N, Norris L, Schulz R, Bennett CL. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10;35(17):1945-1951
323. Lim EA, Gunther JE, Kim HK, Flexman M, Hibshoosh H, Crew K, Taback B, Campbell J, Kalinsky K, Hielscher A, **Hershman DL**. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017 Apr;162(3):533-540.
324. Wright JD, Desai VB, Chen L, Burke WM, Tergas AI, Hou JY, Accordino M, Ananth CV, Neugut AI, **Hershman DL**. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12.
325. Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, **Hershman DL**. Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. Cancer Invest. 2017 Feb 6:1-13.
326. Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, Ercolano E, Gross CP, **Hershman DL**, Ligibel J, Schmitz K, Li FY, Sanft T, Irwin ML. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors. Obesity (Silver Spring). 2017 Feb;25(2):346-35.
327. Greenlee H, Unger JM, LeBlanc M, Ramsey S, **Hershman DL**. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):21-29.

328. Greenlee H, Molmenti CL, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, **Hershman DL**. Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. J Cancer Surviv. 2016 Dec;10(6):956-963.
329. Halpern JA, Shoag JE, Artis AS, Ballman KV, Sedrakyan A, **Hershman DL**, Wright JD, Shih YC, Hu JC. National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening. JAMA Surg. 2017 Feb 1;152(2):192-198.
330. Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, **Hershman DL**. Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial. Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1491-1502.
331. Greenlee H, **Hershman DL**, Shi Z, Kwan ML, Ergas IJ, Roh JM, Kushi LH. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. J Natl Cancer Inst. 2016 Oct 28;109(2).
332. Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, **Hershman DL**, Wright JD, Tina Shih YC, Nguyen PL, Hu JC. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm. J Urol. 2017 Feb;197(2):363-368.
333. Hu JH, O'Malley P, Chughtai B, Isaacs A, Mao J, Wright JD, **Hershman DL**, Sedrakyan A. Comparative Effectiveness of Cancer Control and Survival After Robot Assisted versus Open Radical Prostatectomy. J Urol. 2017 Jan;197(1):115-121.
334. Yoon L, Clarke Hillyer G, Chen L, Hu JC, Neugut AI, **Hershman DL**, Wright JD. Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. Cancer Invest. 2016 Sep 13;34(8):408-14.
335. Govindappagari S, Friedman AM, Chen L, Ananth CV, D'Alton ME, **Hershman DL**, Wright JD. Using Publicly Reported Hospital Data to Predict Obstetric Quality. J Matern Fetal Neonatal Med. 2016 Sep 14:1-24.
336. Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Utilization and Outcomes of Sentinel Lymph Node Biopsy for Vulvar Cancer. Obstet Gynecol. 2016 Oct;128(4):754-60.
337. Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, **Hershman DL**, Wright JD, Tina Shih YC, Nguyen PL, Hu JC. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm. J Urol. 2017 Feb;197(2):363-368.
338. Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, **Hershman DL**. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016 Aug 26;108(12):djw168.
339. Wright JD, Chen L, Burke WM, Hou JY, Tergas AI, Ananth CV, **Hershman DL**. Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. JAMA. 2016 Aug 23-30;316(8):877-8.
340. Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, **Hershman DL**. Long-term diet and biomarker changes after a short-term intervention among Hispanic breast cancer survivors: The ¡Cocinar Para Su Salud! randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1491-1502.
341. Yang J, Neugut AI, Wright JD, Accordino M, **Hershman DL**. Nonadherence to Oral Medications for Chronic Conditions in Breast Cancer Survivors. J Oncol Pract. 2016 Aug;12(8):e800-9.

342. Coromilas EJ, Wright JD, Huang Y, Feldman S, Neugut AI, Hillyer GC, Chen L, **Hershman DL**. Axillary evaluation and lymphedema in women with ductal carcinoma in situ. Breast Cancer Res Treat. 2016 Jul;158(2):373-84.
343. **Hershman DL**, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016 Sep 1;34(25):3014-22.
344. Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, **Hershman DL**. Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. Clin Transl Oncol. 2017 Feb;19(2):180-188.
345. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Buono DL, Nathanson SD, Bovbjerg DH, Mandelblatt JS, Tsai WY, Jacobson JS, **Hershman DL**. A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2016 Jul;158(1):127-38.
346. Neugut AI, Zhong X, Wright JD, Accordino M, Yang J, **Hershman DL**. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. JAMA Oncol 2016 Oct 1;2(10):1326-1332.
347. Zacharia BE, Youngerman BE, Bruce SS, **Hershman DL**, Neugut AI, Bruce JN, Wright JD. Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery. Neurosurgery. 2017 Jan 1;80(1):73-81.
348. Greenlee H, Neugut AI, Falci L, Hillyer GC, Buono D, Mandelblatt JS, Roh JM, Ergas IJ, Kwan ML, Lee M, Tsai WY, Shi Z, Lamerato L, Kushi LH, **Hershman DL**. Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study. JAMA Oncol. 2016 Sep 1;2(9):1170-6.
349. Aycinena AC, Jennings KA, Gaffney AO, Koch PA, Contento IR, Gonzalez M, Guidon E, Karmally W, **Hershman DL**, Greenlee H. ¡Cocinar Para Su Salud! Development of a Culturally Based Nutrition Education Curriculum for Hispanic Breast Cancer Survivors Using a Theory-Driven Procedural Model. Health Educ Behav. 2017 Feb;44(1):13-22.
350. Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, Hu JC, **Hershman DL**. Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. J Clin Oncol. 2016 Aug 20;34(24):2820-6.
351. Wright JD, Hou JY, Burke WM, Tergas AI, Chen L, Hu JC, Ananth CV, Neugut AI, **Hershman DL**. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. Obstet Gynecol. Jun;127(6):985-991.
352. Chatterjee S, Chen L, Tergas AI, Burke WM, Hou JY, Hu JC, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer. Obstet Gynecol. 2016 Jun;127(6):992-1002.
353. Hu JC, Chughtai B, O'Malley P, Halpern JA, Mao J, Scherr DS, **Hershman DL**, Wright JD, Sedrakyan A. Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study. Eur Urol. 2016 Jul;70(1):195-202.
354. Greenlee H, Molmenti CL, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, **Hershman DL**. Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. J Cancer Surviv. 2016 Dec;10(6):956-963.
355. **Hershman DL**, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, Bovbjerg DH, Mandelblatt JS, Tsai WY, Zhong X, Jacobson JS, Wright JD, Neugut AI. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016 May;157(1):133-43.

356. Cui Z, Wright JD, Accordini MK, Buono D, Neugut AI, Hu JC, **Hershman DL**. Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. Cancer Invest. 2016 Apr 20;34(4):189-96.
357. Wright JD, Chen L, Jorge S, Burke WM, Tergas AI, Hou JY, Hu JC, Neugut AI, Ananth CV, **Hershman DL**. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecol Oncol. 2016 Jun;141(3):531-537.
358. Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, **Hershman DL**. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016 Apr;156(3):453-464.
359. Tergas AI, Neugut AI, Chen L, Burke WM, **Hershman DL**, Wright JD. Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. Cancer Invest. 2016 Mar 15;34(3):137-147.
360. Lin CC, Bruinooge SS, Kirkwood MK, **Hershman DL**, Jemal A, Guadagnolo BA, Yu JB, Hopkins S, Goldstein M, Bajorin D, Giordano SH, Kosty M, Arnone A, Hanley A, Stevens S, Olsen C. Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):719-28.
361. Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, **Hershman DL**. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. JAMA Oncol. 2016 Jul 1;2(7):875-81.
362. Unger JM, **Hershman DL**, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD. Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients Future Oncol. 2016 May;12(10):1219-31.
363. Lee SM, Backenroth D, Cheung YK, **Hershman DL**, Vulih D, Anderson B, Ivy P, Minasian L. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials. J Clin Oncol. 2016 Apr 20;34(12):1395-401.
364. John GM, **Hershman DL**, Falci L, Shi Z, Tsai WY, Greenlee H. Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv. 2016 Oct;10(5):850-64.
365. Zhong X, Lim EA, **Hershman DL**, Moinpour CM, Unger J, Lee SM. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. J Oncol Pract. 2016 Mar;12(3):245-6.
366. Wright JD, Tergas AI, Hou JY, Burke WM, Chen L, Hu JC, Neugut AI, Ananth CV, **Hershman DL**. Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. JAMA Surg. 2016 Jul 1;151(7):612-20.
367. Wright JD, Chen L, Tergas AI, Accordini M, Ananth CV, Neugut AI, **Hershman DL**. Underuse of BRCA testing in patients with breast and ovarian cancer. Am J Obstet Gynecol. 2016 Jun;214(6):761-3.
368. Wright JD, Margolis B, Hou JY, Burke WM, Tergas AI, Huang Y, Hu JC, Ananth CV, Neugut AI, **Hershman DL**. Overuse of external beam radiotherapy for stage I endometrial cancer. Am J Obstet Gynecol. 2016 Jul;215(1):75.e1-7.
369. Margolis B, Tergas AI, Chen L, Hou JY, Burke WM, Hu JC, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Natural history and outcome of neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2016 May;141(2):247-254.
370. Wright JD, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Hillyer GC, Ananth CV, Neugut AI, **Hershman DL**. Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors. Obstet Gynecol. 2016 Mar;127(3):449-58.

371. Wright JD, Burke WM, Tergas AI, Hou JY, Huang Y, Hu JC, Hillyer GC, Ananth CV, Neugut AI, **Hershman DL**. Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. J Clin Oncol. 2016 Apr 1;34(10):1087-96.
372. Aycinena AC, Valdovinos C, Crew KD, Tsai WY, Mata JM, Sandoval R, **Hershman D**, Greenlee H. Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors. J Immigr Minor Health. 2017 Feb;19(1):120-129.
373. Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, Ercolano E, Zhou Y, Sanft T, Gross C, Schmitz K, Neogi T, **Hershman DL**, Ligibel J, Irwin ML. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study. J Cancer Surviv. 2016 Aug;10(4):654-62.
374. Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. Gynecol Oncol. 2016 Mar;140(3):387-93.
375. **Hershman DL**, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol. 2015 Dec 23:1-9.
376. Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim Kim J, **Hershman DL**. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS One. 2015 Dec 28;10(12):e0145816.
377. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, **Hershman DL**, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer. 2016 Mar;24(3):1439-47.
378. Wright JD, Huang Y, Burke WM, Tergas AI, Hou JY, Hu JC, Neugut AI, Ananth CV, **Hershman DL**. Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer. Obstet Gynecol. 2016 Jan;127(1):109-18.
379. Wright JD, Jorge S, Tergas AI, Hou JY, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, **Hershman DL**. Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. Obstet Gynecol. 2016 Jan;127(1):101-8.
380. Bernard-Davila B, Aycinena AC, Richardson J, Gaffney AO, Koch P, Contento I, Molmenti CS, Alvarez M, **Hershman DL**, Greenlee H. Barriers and facilitators to recruitment to a culturally-based dietary intervention among urban Hispanic breast cancer survivors. J Racial Ethn Health Disparities. 2015 Jun;2(2):244-255.
381. Unger JM, Gralow JR, Albain KS, Ramsey SD, **Hershman DL**. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. 2015 Oct 15:1-3.
382. Wright JD, Cui RR, Wang A, Chen L, Tergas AI, Burke WM, Ananth CV, Hou JY, Neugut AI, Temkin SM, Wang YC, **Hershman DL**. Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. J. Natl Cancer Inst. 2015 Oct 8;107(11).
383. Accordino MK, Wright JD, Vasani S, Neugut AI, Tergas A, Hu JC, **Hershman DL**. Serum Tumor Marker Use in Patients With Advanced Solid Tumors. J Oncol Pract. 2016 Jan;12(1):65-6.
384. Ligibel JA, Alfano CM, **Hershman DL**, Ballard RM, Bruinooge SS, Courneya KS, Daniels EC, Demark-Wahnefried W, Frank ES, Goodwin PJ, Irwin ML, Levit LA, McCaskill-Stevens W, Minasian LM, O'Rourke MA, Pierce JP, Stein KD, Thomson CA, Hudis CA. Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. J Clin Oncol. 2015 Nov 20;33(33):3961-7.
385. Chamie K, Williams SB, **Hershman DL**, Wright JD, Nguyen PL, Hu JC. Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer. 2015 Dec 1;121(23):4150-7.

386. Lin CC, Bruinooge SS, Kirkwood MK, Olsen C, Jemal A, Bajorin D, Giordano SH, Goldstein M, Guadagnolo BA, Kosty M, Hopkins S, Yu JB, Arnone A, Hanley A, Stevens S, **Hershman DL**. Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. J Clin Oncol. 2015 Oct 1;33(28):3177-85.
387. George EM, Burke WM, Hou JY, Tergas AI, Chen L, Neugut AI, Ananth CV, **Hershman DL**, Wright JD. Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynaecological surgery. BJOG. 2016 Feb;123(3):455-61.
388. Wright JD, Chen L, Tergas AI, Burke WM, Hou JY, Neugut AI, Ananth CV, **Hershman DL**. Population-level trends in relative survival for cervical cancer. Am J Obstet Gynecol. 2015 Nov;213(5):670.e1-7
389. Wright JD, Huang Y, Ananth CV, Tergas AI, Duffy C, Deutsch I, Burke WM, Hou JY, Neugut AI, **Hershman DL**. Influence of Treatment Center and Hospital Volume on Survival for Locally Advanced Cervical Cancer. Gynecol Oncol. 2016 Jan;127(1):109-18
390. Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL Jr, Wade JL 3rd, **Hershman DL**. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. J Acupunct Meridian Stud. 2015 Jun;8(3):152-8.
391. Wright JD, Tergas AI, Ananth CV, Burke WM, Hou JY, Chen L, Neugut AI, Richards CA, **Hershman DL**. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. Cancer Invest. Sep 14;33(8):331-9
392. Dinkelspiel HE, Champer M, Hou J, Tergas A, Burke WM, Huang Y, Neugut AI, Ananth CV, **Hershman DL**, Wright JD. Long-term mortality among women with epithelial ovarian cancer. Gynecol Oncol. 2015 Aug;138(2):421-8
393. Malone H, Yang J, **Hershman DL**, Wright JD, Bruce JN, Neugut AI. Complications following stereotactic needle biopsy of intracranial tumors. World Neurosurg. 2015 Oct;84(4):1084-9.
394. Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, Neugut AI, Ananth CV, **Hershman DL**. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 2015 Jun;125(6):1345-52.
395. Patankar S, Burke WM, Hou JY, Tergas AI, Huang Y, Ananth CV, Neugut AI, **Hershman DL**, Wright JD. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol. 2015 Jul;138(1):62-9.
396. **Hershman DL**, Unger JM, Crew KD, Awad D, Dakhil S, Gralow J, Greenlee H, Lew DL, Minasian L, Till C, Wade JL, Meyskens F, Moinpour C. Randomized Multicenter Placebo-Controlled Trial of Omega-3-Fatty Acids for the control of Aromatase Inhibitor-Induced Musculoskeletal Pain (S0927). J Clin Oncol. 2015 Jun 10;33(17):1910-7.
397. Wright JD, Cui R, Wang A, Chen L, Tergas AI, Burke WB, Ananth CV, Hou JY, MD<sup>1,5,6</sup>, Neugut AI, Temekin, S, Wang C, **Hershman DL**. Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. J Natl Cancer Inst. 2015 Oct 8;107(11):djv251.
398. Coromilis E, Wright JD, Huang Y, Feldman S, Neugut AI, Chen L, **Hershman DL**; The influence of shospital and surgeon factors on the prevalence of axillary evaluation in ductal carcinoma in situ. JAMA Oncology. 2015 Jun;1(3):323-32.
399. Feathers A, Aycinena AC, Lovasi GS, Rundle A, Gaffney AO, Richardson J, **Hershman DL**, Koch P, Contento I, Greenlee H. Food environments are relevant to recruitment and adherence in dietary modification trials. Nutr Res. 2015 Jun;35(6):480-8.
400. Reimers LL, Sivasubramanian PS, **Hershman DL**, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast J. 2015 Jul-Aug;21(4):377-86

401. Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY, Valdovinos C, Falci L, Wang Q, Crew KD, Santella RM, **Hershman DL**, Greenlee H. Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, african american, and afro-Caribbean breast cancer survivors. J Nutr. 2015 Apr;145(4):783-90
402. Keegan TH, Kurian AW, Gali K, Tao L, Lichtensztajn DY, **Hershman DL**, Habel LA, Caan BJ, Gomez SL. Am J Public Health. Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System. Am J Public Health. 2015 May;105(5):938-46
403. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, **Hershman D**, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D; Society for Integrative Oncology Guidelines Working Group. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58.
404. Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, **Hershman DL**, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst. 2015 Mar 4;107(3).
405. Dinkelspiel HE, Tergas AI, Zimmerman LA, Burke WM, Hou JY, Chen L, Hillyer G, Neugut AI, **Hershman DL**, Wright JD. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. Gynecol Oncol. 2015 May;137(2):203-9.
406. Wright, JD, Tergas, AI, Cui R, Burke WM, Hou JY, Ananth CV, Burke, Chen L, Neugut AI, **Hershman, DL**. Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy. JAMA Oncol. 2015 Apr;1(1):69-77.
407. Accordino M, Wright JD, Buono D, Neugut AI, **Hershman DL**. Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Cancer Patients. J Oncol Pract. 2015 May;11(3):e351-9.
408. **Hershman DL**, Tsui J, Wright DW, Coromilis, E, Neugut AI. Household net worth, racial disparities and hormonal therapy adherence among women with early stage breast cancer. J. Clin. Oncol. 2015 Mar 20;33(9):1053-9.
409. Wright, JD, Tergas, AI, Ananth, CV, Burke, WM, Chen, L, Neugut, AI, Richards, CA, **Hershman, DL**. Relationship Between Surgical Oncologic Outcomes and Publically Reported Hospital Quality and Satisfaction Measures. J Natl Cancer Inst. 2015 Jan 24;107(3):dju409.
410. Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, **Hershman DL**. ¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors. J Acad Nutr Diet. 2015 May;115(5):709-723.e3.
411. Patankar SS, Tergas AI, Deutsch I, Burke WM, Hou JY, Ananth CV, Huang Y, Neugut AI, **Hershman DL**, Wright JD. High versus low-dose rate brachytherapy for cervical cancer. Gynecol Oncol. 2015 Mar;136(3):534-41.
412. Dessources K, Hou JY, Tergas AI, Burke WM, Ananth CV, Prendergast E, Chen L, Neugut AI, **Hershman DL**, Wright JD. Factors Associated With 30-Day Hospital Readmission After Hysterectomy. Obstet Gynecol. 2015 Feb;125(2):461-470.
413. Unger JM; **Hershman DL**; Martin D; Etzioni R; Barlow WE; LeBlanc M; Ramsey, SR. The Diffusion of Docetaxel in Patients with Metastatic Prostate Cancer. Journal of the National Cancer Institute 014 Dec 24;107(2).
414. Irwin ML, Cartmel B, Gross C, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, **Hershman DL**, Ligibel J. Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors. J Clin Oncol. 2015 Apr 1;33(10):110411.

415. Wright JD, Kostolias A, Ananth CV, Burke WM, Tergas AI, Prendergast E, Ramsey SD, Neugut AI, **Hershman DL**. Comparative effectiveness of robotically assisted compared with laparoscopic adnexal surgery for benign gynecologic disease. *Obstet Gynecol*. 2014 Nov;124(5):886-96.
416. **Hershman DL**, Tsui J, Meyer J, Glied S, Hillyer G, Wright DW, Neugut AI. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. *J Natl Cancer Inst*. 2014 Oct 27; 106(11):dju319.
417. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, **Hershman DL**, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA. American society of clinical oncology position statement on obesity and cancer. *J Clin Oncol*. 2014 Nov 1;32(31):3568-74
418. Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, **Hershman DL**, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD. Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. *Cancer Causes Control*. 2015 Feb;26(2):187-203.
419. **Hershman DL**, Lacchetti C, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline summary. *J Oncol Pract*. 2014 Nov;10(6):e421-4.
420. Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, **Hershman DL**. Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. *Cancer Invest*. 2014 Oct;32(9):439-44.
421. Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, **Hershman DL**, Brown Jr RS, Neugut AI, Emond J, Kato T, Samstein B, Faleck D, Karagozian R. Serum Adiponectin Is Associated with Worsened Overall Survival in a Prospective Cohort of Hepatocellular Carcinoma Patients. *Oncology*. 2014 Oct 3;88(1):57-68.
422. Kwan ML, Lo JC, Tang L, Laurent CA, Roh JM, Chandra M, Hahn TE, Hong CC, Sucheston-Campbell L, **Hershman DL**, Quesenberry CP Jr, Ambrosone CB, Kushi LH, Yao S. Bone health history in breast cancer patients on aromatase inhibitors. *PLoS One*. 2014 Oct 29;9(10):e111477.
423. Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, **Hershman DL**. Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy using Morcellation. *JAMA*. 2014. Sep 24;312(12):1253-5.
424. Mandelblatt JS, Huang K, Makgoeng SB, Luta G, Song JX, Tallarico M, Roh JM, Munneke JR, Houlston CA, McGuckin ME, Cai L, Clarke Hillyer G, **Hershman DL**, Neugut AI, Isaacs C, Kushi L. Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative J *Oncol Pract*. 2015 Jan;11(1):e1-8.
425. Accordino MK, Neugut AI, **Hershman DL**; Cardiac Effects of Anticancer Therapy in the Elderly. *Journal of Clinical Oncology*. 2014 Aug 20;32(24):2654-2661.
426. **Hershman DL**, Neugut AI, Shim JJ, Glied S, Tsai WY, Wright JD. Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies. *J Oncol Pract*. 2014 Jul;10(4):264-9.
427. **Hershman DL**, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2014 Jun 20;32(18):1941-67.
428. Greenlee H, Kwan ML, Ergas IJ, Strizich G, Roh JM, Wilson AT, Lee M, Sherman KJ, Ambrosone CB, **Hershman DL**, Neugut AI, Kushi LH. Changes in vitamin and mineral supplement use after breast cancer diagnosis in the Pathways Study: a prospective cohort study. *BMC Cancer*. 2014 May 29;14:382.

429. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, **Hershman DL**. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer. 2014 Nov;21(6):780-5.
430. Wright JD, Ananth CV, Tergas AI, Herzog TJ, Burke WM, Lewin SN, Lu YS, Neugut AI, **Hershman DL**. An economic analysis of robotically assisted hysterectomy. Obstet Gynecol. 2014 May;123(5):1038-48.
431. Tu Y, **Hershman DL**, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
432. George EM, Tergas AI, Ananth CV, Burke WM, Lewin SN, Prendergast E, Neugut AI, **Hershman DL**, Wright JD. Safety and Tolerance of Radical Hysterectomy for Cervical Cancer in the Elderly. Gynecol Oncol. 2014 Jul;134(1):36-41.
433. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, **Hershman DL**. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun;28(3):272-82.
434. Goss PE, **Hershman DL**, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomized controlled trial. Lancet Oncology. 2014 Apr;15(4):474-82.
435. Unger JM, Barlow W, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, **Hershman DL**. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014 Mar;106(3):dju002.
436. Zacharia BE, Deibert C, Gupta G, **Hershman DL**, Neugut AI, Bruce JN, Spencer BA. Incidence, Cost, and Mortality Associated With Hospital-acquired Conditions Following Resection of Cranial Neoplasms. Neurosurgery. 2014 Jun;74(6):638-47.
437. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, **Hershman DL**. Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. Cancer Invest. 2014 May;32(4):150-7.
438. Smith CB, Kale M, Mhango G, Neugut AI, **Hershman DL**, Mandeli JP, Wisnivesky JP. Comparative Outcomes of Elderly Stage I Lung Cancer Patients Treated with Segmentectomy via Video-Assisted Thoracoscopic Surgery versus Open Resection. J Thorac Oncol. 2014 Mar;9(3):383-9.
439. Wright JD, Ananth CV, Tsui J, Glied SA, Burke WM, Lu YS, Neugut AI, Herzog TJ, **Hershman DL**. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer. 2014 Apr 15;120(8):1246-54.
440. Spencer BA, Shim JJ, **Hershman DL**, Zacharia BE, Lim EA, Benson MC, Neugut AI. Metastatic epidural spinal cord compression among elderly patients with advanced prostate cancer. Support Care Cancer. 2014 Jun;22(6):1549-55.
441. Weinberg A, Wright J, Deibert C, Lu YS, **Hershman DL**, Neugut A, Spencer B. Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy. World J Urol. 2014 Oct;32(5):1313-21.
442. Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, **Hershman DL**, Neugut AI, Bruce JN. The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg. 2014 Feb;120(2):300-8.

443. Wright JD, Hassan K, Ananth CV, Herzog TJ, Lewin SN, Burke WM, Lu YS, Neugut AI, **Hershman DL**. Use of Guideline-Based Antibiotic Prophylaxis in Women Undergoing Gynecologic Surgery. Obstet Gynecol. 2013 Dec;122(6):1145-53.
444. **Hershman DL**. Wright JD, Lim E, Buono D, Tsai WT, Neugut AI, Contraindicated' use of Bevacizumab and Toxicity in Elderly Cancer Patients. J Clin Oncol. 2013 Oct 1;31(28):3592-9.
445. Andreopoulou E, Vigoda IS, Valero V, **Hershman DL**, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013 Oct;141(3):429-35
446. Flexman ML, Kim HK, Gunther JE, Lim EA, Alvarez MC, Desperito E, Kalinsky K, **Hershman DL**, Hielscher AH. Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography. J Biomed Opt. 2013 Sep 1;18(9):
447. Veluswamy RR, Mhango G, Bonomi M, Neugut AI, **Hershman DL**, Aldridge MD, Wisnivesky JP. Adjuvant Treatment for Elderly Patients with Early Stage Lung Cancer Treated with Limited Resection. Ann Am Thorac Soc. 2013 Dec;10(6):622-8.
448. Bashir S, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, Herzog TJ, **Hershman DL**, Wright JD. Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrier. Dis Colon Rectum. 2013 Oct;56(10):1174-84.
449. Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, **Hershman DL**, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014 Jun;14(3):241-7.
450. Wright JD, Ananth CV, Lewin SN, Burke WM, Siddiq Z, Neugut AI, Herzog TJ, **Hershman DL**. Patterns of use of hemostatic agents in patients undergoing major surgery. J Surg Res. 2014 Jan;186(1):458-66.
451. Wright JD, Ananth CV, Ojalvo L, Herzog TJ, Lewin SN, Lu YS, Neugut AI, **Hershman DL**. Failure to rescue after major gynecologic surgery. Am J Obstet Gynecol. 2013 Nov;209(5): 420.e1-8.
452. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, Neugut AI, **Hershman DL**. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol. 2013 Aug;122(2 Pt 1):233-41.
453. Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, **Hershman DL**, Wright JD. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest. 2013 Aug;31(7):500-4.
454. Spencer BA, McBride RB, **Hershman DL**, Buono D, Herr HW, Benson MC, Gupta-Mohile S, Neugut AI. Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 2013 Mar;9(2):92-8.
455. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, **Hershman DL**, Wright JD. Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome. Gynecol Oncol. 2013 Oct;131(1):42-5.
456. Wright JD, Neugut AI, Lewin SN, Lu YS, Herzog TJ, **Hershman DL**. Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol. 2013 Jun;121(6):1217-25.
457. **Hershman DL**, Unger JM, Crew KD, Minasian L, Awad D, Moynour C, Hansen L, Lew D, Greenlee H, Fehrenbacher L, Wade, J, Wong S, Hortobagyi G, Meyskens<sup>1</sup> F, Albain KS. Randomized Placebo Controlled Trial of Acetyl-L-Carnitine For Taxane Induced Neuropathy. J Clin Oncol. Jul 10;31(20):2627-33.

458. Winner M, Mooney SJ, **Hershman DL**, Feingold DL, Allendorf JD, Wright JD, Neugut AI. Incidence and Predictors of Bowel Obstruction in Elderly Patients With Stage IV Colon Cancer: A Population-Based Cohort Study. JAMA Surg. 2013 Jun 5:1-7.
459. Winner M, Mooney SJ, **Hershman DL**, Feingold DL, Allendorf JD, Wright JD, Neugut AI. Management and Outcomes of Bowel Obstruction in Patients with Stage IV Colon Cancer: Population-Based Cohort Study. Dis Colon Rectum. 2013 Jul;56(7):834-843.
460. Kroenke CH, Kwan ML, Neugut AI, Ergas IJ, Wright JD, Caan BJ, **Hershman D**, Kushi LH. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast Cancer Res Treat. 2013 Jun;139(2):515-27.
461. Perera HK, Ananth CV, Richards CA, Neugut AI, Lewin SN, Lu YS, Herzog TJ, **Hershman DL**, Wright JD. Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol. 2013 Apr;121(4):717-26.
462. **Hershman DL**, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Jayasena R, Tsai WY, Neugut AI, Crew KD. Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat. 2013 Apr;138(3):795-806.
463. Sharma C, Deutsch I, Herzog TJ, Lu YS, Neugut AI, Lewin SN, Chao CK, **Hershman DL**, Wright JD. Patterns of care for locally advanced vulvar cancer. Am J Obstet Gynecol. 2013 Jul;209(1):60.
464. Wright JD, Deutsch I, Wilde ET, Ananth CV, Neugut AI, Lewin SN, Siddiq Z, Herzog TJ, **Hershman DL**. Uptake and Outcomes of Intensity-Modulated Radiation Therapy for Uterine Cancer. Gynecol Oncol. 2013 Jul;130(1):43-8.
465. Wright JD, Neugut AI, Ananth CV, Lewin SN, Wilde ET, Lu YS, Herzog TJ, **Hershman DL**. Deviations From Guideline-Based Therapy for Febrile Neutropenia in Cancer Patients and Their Effect on Outcomes. JAMA Intern Med. 2013 Mar 4:1-10.
466. Vin-Raviv N, Clarke Hillyer G, **Hershman DL**, Galea S, Leoce N, Bovbjerg DH, Kushi LH, Kroenke C, Lamerato L, Ambrosone CB, Valdimorsdottir H, Jandorf L, Mandelblatt JS, Tsai WY, Neugut AI. Racial Disparities in Posttraumatic Stress After Diagnosis of Localized Breast Cancer: The BQUAL Study. J Natl Cancer Inst. 2013 Apr 17;105(8):563-72.
467. Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS, Neugut AI, Herzog TJ, **Hershman DL**. Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA. 2013 Feb 20;309(7):689-98.
468. Matushansky I, Dela Cruz F, Insel BJ, **Hershman DL**, Neugut AI. Chemotherapy Use in Elderly Patients With Soft Tissue Sarcoma: A Population-Based Study. Cancer Invest. 2013 Feb;31(2):83-91.
469. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, **Hershman DL**, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat. 2013 Feb;137(3):903-13. doi: 10.1007/s10549-012-2400-2. Epub 2013 Jan 10.
470. Unger JM, **Hershman DL**, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ. Patient Income Level and Cancer Clinical Trial Participation. J Clin Oncol. 2013 Feb 10;31(5):536-42.
471. Spencer BA, Insel BJ, **Hershman DL**, Benson MC, Neugut AI. Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer. Support Care Cancer. 2013 May;21(5):1303-11.
472. Wright JD, Neugut AI, Wilde ET, Buono DL, Tsai WY, **Hershman DL**. Use and benefits of laparoscopic hysterectomy for stage I endometrial cancer among medicare beneficiaries. J Oncol Pract. 2012 Sep;8(5):389-99.

473. Clarke Hillyer G, Neugut AI, Crew KD, Kalinsky K, Maurer MA, Rotsides DZ, Danaceau J, **Hershman DL**. Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. J Oncol Pract. 2012 Sep;8(5) e100-4.
474. Mooney SJ, Winner M, **Hershman DL**, Wright JD, Feingold DL, Allendorf JD, Neugut AI. Bowel Obstruction in Elderly Ovarian Cancer Patients: A Population-Based Study. Gynecol Oncol. 2013 Apr;129(1):107-12.
475. Shelton RC, Hillyer GC, **Hershman DL**, Leoce N, Bovbjerg DH, Mandelblatt JS, Kushi LH, Lamerato L, David Nathanson S, Ambrosone CB, Neugut AI. Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. Breast Cancer Res Treat. 2013 Feb;137(3):817-28
476. Kurian AW, Lichtensztajn DY, Keegan TH, Leung RW, Shema SJ, **Hershman DL**, Kushi LH, Habel LA, Kolevska T, Caan BJ, Gomez SL. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan;137(1):247-60.
477. Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, **Hershman DL**. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013 Apr;21(4):1077-87.
478. Hillyer GC, **Hershman DL**, Kushi LH, Lamerato L, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Rana S, Neugut AI. A survey of breast cancer physicians regarding patient involvement in breast cancer treatment decisions. Breast. 2013 Aug;22(4):548-54.
479. Schiavone MB, Herzog TJ, Ananth CV, Wilde ET, Lewin SN, Burke WM, Lu YS, Neugut AI, **Hershman DL**, Wright JD. Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. Am J Obstet Gynecol. 2012 Nov;207(5):382.e1-9.
480. **Hershman DL**, Wright JD. Comparative Effectiveness Research in Oncology Methodology: Observational Data. J Clin Oncol. 2012 Dec 1;30(34):4215-22.
481. Wright JD, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM, Lewin SN, Ananth CV, **Hershman DL**. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol. 2012 Nov 10;30(32):3976-82. doi: 10.1200/JCO.2012.43.2906.
482. **Hershman, DL**; Neugut, AI; Richards, CA; Kalinsky, K; Charles, AS; Wright, JD. Influence of hospital factors, physician factors and type of health insurance on receipt of immediate post mastectomy reconstruction in young women with breast cancer. Breast Cancer Research and Treatment, 2012 Nov;136(2):535-45.
483. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Magai C, Tsai WY, Jacobson JS, **Hershman DL**. Noninitiation of Adjuvant Chemotherapy in Women With Localized Breast Cancer: The Breast Cancer Quality of Care Study. J Clin Oncol. 2012 Nov 1;30(31):3800-9.
484. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, **Hershman DL**. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol. 2012 Oct;120(4):871-81.
485. Siegel AB, Conner K, Wang S, Jacobson JS, **Hershman DL**, Hidalgo R, Verna EC, Halazun K, Brubaker W, Zaretsky J, Moniodis A, Delgado-Cruzata L, Dove L, Emond J, Kato T, Brown RS Jr, Neugut AI. Smoking and hepatocellular carcinoma mortality. Exp Ther Med. 2012 Jan;3(1):124-128.
486. Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, **Hershman DL**, Agrapart V, Ananthakrishnan R, Staroslawska E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. Jan;24(1):109-16
487. Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, Jacobson JS, **Hershman DL**, C Verna E, Zaretsky J, Halazun K, Dove L, Brown RS Jr, Neugut AI, Kato T, Remotti H, Coppleson YJ,

- Emond JC. Diabetes, Body Mass Index, and Outcomes in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation. Transplantation. 2012 Sep 15;94(5):539-543.
488. Schiavone MB, Kuo EC, Naumann RW, Burke WM, Lewin SN, Neugut AI, **Hershman DL**, Herzog TJ, Wright JD. The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. Am J Obstet Gynecol. 2012 Sep;207(3):174.e1-7.
489. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, **Hershman DL**. Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. Gynecol Oncol. 2012 Oct;127(1):11-7.
490. Crew KD, Brown P, Greenlee H, Bevers TB, Arun BK, Hudis CA, McArthur HL, Chang J, Rimawi MF, Vornik L, Cornelison TL, Wang A, Hibshoosh HH, Ahmed A, Terry MB, Santella RM, Lippman SM, **Hershman DL**. Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer. Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54.
491. Greenlee H, Crew K, Mata J, McKinley PS, Rundle A, Zhang W, Liao Y, Tsai WY, **Hershman DL**. A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors. Obesity. 2013 Jan;21(1):65-76.
492. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, **Hershman DL**. Comparative Effectiveness of Minimally Invasive and Abdominal Radical Hysterectomy for Cervical Cancer. Gynecol Oncol. 2012 Oct;127(1):11-7.
493. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, **Hershman DL**, Wright JD. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012 May;125(2):287-91.
494. Berger-Chen S, Herzog TJ, Lewin SN, Burke WM, Neugut AI, **Hershman DL**, Wright JD. Access to conservative surgical therapy for adolescents with benign ovarian masses. Obstet Gynecol. 2012 Feb;119(2 Pt 1):270-5.
495. Wallenstein MR, Ananth CV, Kim JH, Burke WM, **Hershman DL**, Lewin SN, Neugut AI, Lu YS, Herzog TJ, Wright JD. Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol. 2012 Apr;119(4):709-16.
496. Neugut, AI; Hillyer, GC; Kushi, LH; Lamerato, L; Nathanson, D; Ambrosone, CB; Bovbjerg, DH; Mandelblatt, JS; Magai, C; Tsai, WY; Jacobson, JS; **Hershman, DL**. Non-initiation of adjuvant hormonal therapy in women with hormone receptor positive breast Cancer: The Breast Cancer Quality of Care Study (B-QUAL). Breast Cancer Res Treat. 2012 Jul;134(1):419-28.
497. Ramaswamy, B; Fiskus, W; Cohen, B; Pellegrino, C; **Hershman, DL**; Chuang, E; Luu, T; Somlo, G; Goetz, M; Swaby, R; Shapiro, CL; Stearns, V; Christos, P; Espinoza-Delgado, I; Bhalla, K; Sparano, JA. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer; evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012 Apr;132(3):1063-72.
498. Wright JD, **Hershman DL**, Burke WM, Sun X, Neugut AI, Lewin SN, Herzog TJ. Influence of surgical volume on outcome of laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol. 2012 Mar;19(3):948-58.
499. Wright JD, **Hershman DL**, Shah M, Burke WM, Sun X, Neugut AI, Lewin SN, Herzog TJ. Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery. Obstet Gynecol. 2011 Nov;118(5):978-86.
500. Sharma, C; Deutsch, I; Horowitz, DP; **Hershman, DL**; Lewin, SN; Lu, YS; Neugut, TJ; Chao, CK; Wright, JD. Cancer. Jul 15;118(14):3618-26.
501. Neugut, AI; Hillyer, GC; Kushi, LH; Lamerato, L; Nathanson, D; Ambrosone, CB; Bovbjerg, DH; Mandelblatt, JS; Magai, C; Tsai, WY; Jacobson, JS; **Hershman, DL**. The Breast Cancer Quality of

- Care Study (B-QUAL): A multi-center study to determine causes for non-compliance with breast cancer adjuvant therapy Breast Journal. 2012 May-Jun;18(3):203-13
502. Wright JD; Lewin, SN; Deutsch I; Burke W; Sun X; Neugut AI; Herzog, TJ; **Hershman, DL**. Defining the Limits of Radical Cytoreductive Surgery for Ovarian Cancer. Gynecol Oncol. 2011 Dec;123(3) 467-73.
503. **Hershman, DL**; Wilde, ET; Wright, JD; Buono, DL; Kalinsky, K; Tsai, WY; Neugut, AI. Uptake and economic impact of first-cycle colony stimulating factor use for the adjuvant treatment of breast cancer. Journal of Clinical Oncology. 2012 Mar 10;30(8):806-12
504. Neugut, AI; Becker D; Insel, BJ; **Hershman, DL**. Uptake of Oxaliplatin and Bevacizumab for the treatment of node positive and metastatic colon cancer. J Oncol Practice , 2012 May;8(3):156-63
505. Wright JD; Burke W; Lewin, SN; Charles, AS; Kim, J; Neugut AI; Herzog, TJ; **Hershman, DL**. Comparative Effectiveness of Robotic versus Laparoscopic Hysterectomy for Endometrial Cancer. Journal of Clinical Oncology. 2012 Mar 10;30(8):783-91.
506. Livaudais JC; Hershman DL; Deutsch I; Burke WM; Sun X; Neugut AI; Herzog TJ; **Hershman DL**. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
507. Wright, JD; Neugut, AI; Wilde, ET; Buono, DL; Malin, J; <sup>3</sup>; Tsai, WY; **Hershman, DL**. Physicians Characteristics and Variability of Erythropoiesis-Stimulating Agent Use Among Medicare Patients with Cancer. Journal of Clinical Oncology. 2011 Sep 1;29(25):3408-18.
508. Neugut, AI; Subar, M; Wilde, E; Stratton, S; Brouse, C; Hillyer, G; Grann, VR; **Hershman, DL**. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early stage breast cancer. Journal of Clinical Oncology. 2011 Jun 20;29(18):2534-42.
509. Sucheston L, Zhao H, Yao S, Zirpoli G, Barlow WE, Budd GT, **Hershman DL**, Davis W, Ciupak G, Stewart J, Isaacs C, Hobday T, Latreille J, Hortobagyi GN, Gralow J, Livingston R, Albain K, Hayes DF, Ambrosone CB. Genetic Predictors of Taxane-induced Neurotoxicity: Results from a SWOG Clinical Trial for Breast Cancer. Breast Cancer Res Treat. 2011 Dec;130(3):993-1002
510. Flexman, ML; Khalil, MA; Abdi, RA; Kim, HK; Fong, CJ; Desperito, E; **Hershman, DL**; Barbour, RL; Hielscher, AH. Digital Optical Tomography system for dynamic breast imaging. J Biomed Opt. 2011 Jul;16(7):076014.
511. Lee, SL; **Hershman, DL**; Martin, P; Leonard, J; Cheung, K; Validation of toxicity burden score for use in phase I clinical trials. Ann Oncol. 2012 Feb;23(2):537-41.
512. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, **Hershman DL**, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE Evaluation of metformin in early stage breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011 Apr;126(2):529-37.
513. Siegel AB, Wang S, Jacobson JS, Hershman DL, Lim EA, Yu J, Ferrante L, Devaraj KM, Remotti H, Scudato S, Halazun K, Emond J, Dove L, Brown RS Jr, Neugut AI. Obesity and microvascular invasion in hepatocellular cancer. Cancer Invest. 2010 Dec;28(10):1063-9.
514. **Hershman, DL**; Weimer, LH; Braffman, L; Fuentes, D; Awad, D; Crew, KD; Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011 Feb;125(3):767-74.
515. **Hershman, DL**; Kushi, L; Kershbaum, A; Shao, T; Tsai, W; Gomez, S; Miles, S; Neugut, AI. Non-adherence among early stage breast cancer patients treated with adjuvant hormonal therapy and survival. Breast Cancer Res Treat. 2011 Apr;126(2):529-37.

516. Grann, VR; Patel, RP; Jacobson, JS; Warner, L; Heitjan, DF; Ashby-Thompson, M; **Hershman, DL**; Neugut, AI. Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2011 Feb;125(3):837-47.
517. **Hershman, DL**; Kushi, L; Kershenbaum, A; Shao, T; Tsai, W; Gomez, S; Miles, S; Neugut, AI. Early discontinuation and non-adherence among early stage breast cancer patients treated with adjuvant hormonal therapy. Journal of Clinical Oncology. 2010 Sep 20;28(27):4120-8.
518. McBride, RB; Lebwol, B; **Hershman, DL**; Neugut, AI. Impact of Socioeconomic Status on Extent of Lymph Node Dissection for Colon Cancer. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):738-45.
519. Goldsmith RE, Jandorf L, Valdimarsdottir H, Amend KL, Stoudt BG, Rini C, **Hershman D**, Neugut A, Reilly JJ, Tartter PI, Feldman SM, Ambrosone CB, Bovbjerg DH. Traumatic stress symptoms and breast cancer: the role of childhood abuse. Child Abuse Negl. 2010 Jun;34(6):465-70.
520. Kwan, ML; Ergas, IJ; Somkin, CP; Quesenberry, CP J.; Neugut, AI; **Hershman, DL**; Mandelblatt, J; Pelayo, MP; Timperi, AW; Miles, SQ; Kushi, LH. Quality of life among women recently diagnosed with invasive breast cancer: The Pathways Study. Breast Cancer Research and Treatment. 2010 Sep;123(2):507-24.
521. Tager, FA; McKinley, P; Schnabel, F; El-Tamer, M; Chung, Y; Fang, Y; Golden, CR; Frosch, M; Habif, U.; Mulligan, MM; **Hershman, DL**. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Research and Treatment. 2010 Aug;123(1):25-34.
522. Fu, O; Crew, KD; Jacobson, JS; Greenlee, H; Yu, G; Campbell, J; Ortiz, Y; **Hershman, DL**; Persistent Treatment-Related Symptoms Associated with Ethnicity and Employment in Breast Cancer Survivors. J Cancer Surviv. 2009 Dec;3(4):241-50.
523. Yu, B; Lobo, R; Ferin, MJ; Douglas, N; Nakhuda, GS; and **Hershman, DL**. Predictive Markers of Chemotherapy-Induced Menopause in Premenopausal Women under the age of 40 with Breast Cancer. Cancer. 2010 Apr 1;116(7):1801-9.
524. **Hershman, DL**; McMahon, D; Crew, K; Shao, T; Cremers, S; Irani, D; Brafman, L; Awad, D; Shane, E. One year of Zoledronic acid prevents bone loss for up to 2 years in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Journal of Clinical Endocrinology and Metabolism. 2010 Feb;95(2):559-66.
525. Crew KD, Capodice J, Greenlee H, Braffman L, Fuentes D, Awad, D; Tsai, W; **Hershman DL**. Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early stage breast cancer. Journal of Clinical Oncology. 2010 Mar 1;28(7):1154-60.
526. **Hershman, DL**; Hurley, D; Wong, M; Morrison, V; Malin, J. The Impact of Primary Prophylaxis on Febrile Neutropenia within Community Practices in the United States. Journal of Medical Economics. 2009 Sep;12(3):203-10.
527. Yu, JC; Neugut, AI; Wang, S; **Hershman, DL**; Jacobson, JS; Moss, J; Scrudato, S; Khungar, V; Lim, E; Brown, RS; Siegel, AS. Race, insurance, and receipt of surgery among patients with hepatocellular carcinoma. CANCER. 2010 Feb 8;116(7):1801-1809.
528. **Hershman, DL**; Buono, D; McBride, R; Tsai, W; Neugut, AI. Erythrocyte Stimulating Agents use in Medicare patients with Cancer Receiving Chemotherapy. Journal of the National Cancer Institute. 2009 Dec 2;101(23):1633-41.
529. Lai, R; **Hershman, DL**; Doan, T; Neugut, AI. Timing of Cranial Radiation in Elderly Patients with Newly Diagnosed Glioblastoma Multiforme.. Neuro Oncology. 2010 Feb;12(2):190-8.
530. Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, **Hershman D**, Goldman N, Ivy PS, Runowicz CD, Muggia F, Goldberg GL, Einstein MH. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. Gynecol Oncol. 2010 Mar;116(3):442-6.

531. Abrams, J; Buono, D; Strause, J; McBride, R; **Hershman, DL**; Neugut, AI. Esophagectomy Compared to Chemoradiation for Early Stage Esophageal Cancer in the Elderly. Cancer. 2009 Nov 1;115(21):4924-33.
532. Strause, J; **Hershman, DL**; Buono, D; McBride, RB; Clark-Garvey, S; Abrams, J; Neugut, AI; Use of Adjuvant 5-Fluorouracil and Radiation Therapy for Gastric Cancer among the Elderly: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1404-12.
533. Albain, K; Unger, J; Hutchens, L; Livingston, R; Crowley, J; Coltman, C. **Hershman, D**; Racial Disparities in Survival in Patients with Gender-Specific Cancers Treated on Southwest Oncology Group Clinical Trials. Journal of the National Cancer Institute. 2009. Jul 15; 101(14):984-992. *Editorial*: Brawly, O. Is race really a negative prognostic factor for cancer?
534. Greenlee, H; Gammon, M; Abrahamson, P; Gaudet, M; Terry, MB; **Hershman, DL**; Desai, M; Teitelbaum, SL; Neugut, AI; Jacobson, JS. Prevalence and predictors of antioxidant supplement use during breast cancer treatment: The Long Island Breast Cancer Study Project. CANCER. 2009; Jul 15;115(14):3271-3282
535. Crew, K; Gammon, M; Steck, S; **Hershman DL**; Cremers, S; Dworakowski, E; Shane, E; Terry, MB; Desai, M; Teitelbaum, S; Neugut, AI; Santella, RM.. Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk. Journal of Cancer Prevention. 2009 Jun;2(6):598-604.
536. **Hershman, DL**; Buono, D; McBride, R; Tsai, W; Neugut, AI; Influence of Private Practice Setting on Adjuvant Chemotherapy for Elderly Women with Early-Stage Breast Cancer. Cancer. 2009; Sep 1;115(17):3848-3857
537. Crew, KD; Shane, E; Cremers, E; McMahon, DJ; Irani, D; **Hershman, DL**; High Prevalence of Vitamin D Deficiency Following Supplementation in Premenopausal Women with Breast Cancer Undergoing Adjuvant Chemotherapy. Journal of Clinical Oncology. 2009 May 1;27(13):2151-2156.. *Editorial*. Goodwin, P. **Vitamin D in Cancer Patients: Above All, Do No Harm.**
538. **Hershman, DL**; Unger, J; Barlow, W; Hutchens, L; Martino, S; Livingston, R; Albain, K; Treatment Quality and Outcome of African American vs. Caucasian Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Group Studies S8814/S8897. 2009 May 1;27(13):2157-2162. Journal of Clinical Oncology. *Editorial*. Hassett, MJ, Griggs, JJ: **Disparities in Breast Cancer Adjuvant Chemotherapy: Moving Beyond Yes or No.**
539. **Hershman, D**; Buono, D; Jacobson, J; McBride, R; Joseph, KA; Tsai, W Surgeon characteristics and receipt of breast conservation therapy in women with breast cancer. Annals of Surgery. 2009 May;249(5):828-833.
540. Li, T; Christos,P; Sparano, JA; **Hershman, DL**; O'Brien, K; Hoschander, J; Wright, J; Vahdat, LT. Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer. Annals of Oncology. 2009. Apr;20(4):642-647.
541. Grann, V; Patel, P; Bharthuar, A; Jacobson, J; Warner, E; Anderson, K; Warner, E; Tsai, W; Hill, KA; Neugut, A; **Hershman, D**. Breast cancer-related preferences among women with and without BRCA mutation. Breast Cancer Research and Treatment. 2010 Jan;119(1):177-84.
542. Sparano, J, Moulder, S, Kazi, A, Coppola, D, Negassa, A, Vahdat, L, Li, T, Pellegrino, C, Fineberg, S, Munster, P, Malafa, M, Lee, D, Hoschander, S, Hopkins, U, **Hershman, D**, Wright, J, Kleer, C, Merajver, S, Sebti, S; Phase II trial of the farnesyl transferase inhibitor tipifarnib plus neoadjuvant dose-dense doxorubicin-cyclophosphamide in patients with locally advanced breast cancer. Clinical Cancer Research. 2008 Mar;14(2):162-167.
543. Grann, V; Ziv, E; Joseph, C; Wei, Y; Jacobson, JS; Horwitz, MS; Bowman, N; and **Hershman, DL**. Duffy (Fy), DARC, and Neutropenia among Women from the United States, Europe, and the Caribbean. British Journal of Hematology. 2008 Oct;143(2):288-293.
544. **Hershman, D**; McMahon, D; Crew, K; Cremers, S; Irani, D; Cucchiara, G; Brafman, L; Sierra, A; Shane, E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant

- chemotherapy for early stage breast cancer. Oct 10;26(29):4739-45. Journal of Clinical Oncology. 2008. Oct 10;26(29):4739-45.
545. **Hershman, D**; Calhoun, E; Zapert, K; Wade, S; Malin, J; Barron, R. Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy. Arch Drug Inf. 2008 Sep;1(2):70-78.
546. Grann, V; Bowman, N; Joseph, C; Wei, Y; Horwitz, MS; Jacobson, JS; and **Hershman, DL**. Neutropenia in six ethnic groups from the Caribbean and the United States. CANCER. 2008 Aug 15;113(4):854-860.
547. Cohen, A; Fleischer, J; Johnson, M; Brown, I; Joe, A; **Hershman, DL**; McMahon, D; Silverberg, SJ. Prevention of bone loss after withdrawal of tamoxifen. Endoc. Pract. 2008 Mar;14(2):162-167.
548. Wright, J; Tieu, D; McBride, R; Jacobson, J; **Hershman, D**; Variability in Chemotherapy Delivery for Women with Advanced Stage Ovarian Cancer and its Impact on Survival. British Journal of Cancer. 2008. Apr 8;98(7):1197-1203.
549. **Hershman, DL**; McBride, RB; Eisenberger, A; Grann, V; Tsai, W; Jacobson, J. Doxorubicin, cardiac risk factors and cardiac toxicity in elderly patients with diffuse b-cell non-Hodgkin's lymphoma. 2008; 26(19):3159-3165 Journal of Clinical Oncology. EDITORIAL: Carver, J; Schuster, SJ; Glick, JH. Doxorubicin Cardiotoxicity in the Elderly: Old Drugs and New Opportunities.
550. **Hershman, D**; Buono, D; McBride, R; Joseph, KA; Grann, V; Tsai, W.; Jacobson, J; Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. Journal of the National Cancer Institute. 2008 Feb 6;100(3):199-206.
551. Kaufman, EL; Jacobson, JS; **Hershman, DL**, Desai, MD; Neugut, AI. Effect of Breast Cancer Radiotherapy and Cigarette Smoking on Risk of Second Primary Lung Cancer. Journal of Clinical Oncology. Jan 20;26(3):392-398. 2008
552. Wang, X; **Hershman, D**; Abrams, J; Jacobson, J; Grann, V; Neugut, A. Predicators of Survival after Hepatic Resections among Patients with Colorectal Liver Metastasis: a Population Based Study. Br J Cancer. 2007 Dec 17;97(12):1606-1612
553. Siegel, A;McBride, R; Ell-Serag, H; **Hershman, D**; Brown, R; Zablotska, L; Neugut, AI Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002.. American Journal Of Gastroenterology. 2008 Jan;103(1):120-127
554. Siegel, A; McBride, R; Ell-Serag, H; **Hershman, D**; Brown, R; Zablotska, L; Neugut, AI The Risk of Hepatocellular Carcinoma in Patients with Previous Malignancy. Cancer Investigation. 2007; Jun;26(5):511-515.
555. Crew, K; Capodice J; Greenlee H; Jacobson, J; Raptis GR; Blozie K; Sierra A; **Hershman D**. Effect of acupuncture on joint symptoms induced by adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patient. Journal of Cancer Survivorship. 2007; (1) 283-291.
556. Taylor, C; **Hershman, D**; Shah, N; Suciu-Foca, N; Petrylak, P; Taub, R; Vahdat, L; Cheng, B; Pegram, M; Knutson, K; Clynes, R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research. 2007 Sep 1;13(17):5133-5143
557. McBride, RB; **Hershman, D**; Tsai, W, Jacobson, JS; Grann, VR; Neugut, AI. Within-stage racial differences in tumor size and number of positive lymph nodes in women with breast cancer. CANCER. 2007 Sep 15;110(6):1201-1208.
558. Magai C, Consedine, N, **Hershman, DL**., Neugut, AI Psychosocial Influences on Sub-optimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention. Health Education and Behavior. 2008 Dec;35(6):835-854.
559. Magai C, Consedine, N, Neugut, AI, **Hershman, DL**. Common psychosocial factors underlying breast cancer screening and breast cancer treatment adherence: a conceptual review and synthesis. J Womens Health (Larchmt). 2007 Jan-Feb;16(1)11-23.

560. Crew K, Apollo AJ, Greenlee H, Raptis GR, Braffman L, Fuentes D, **Hershman D**. Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer Journal of Clinical Oncology. 2007;25(25):3877-3883. EDITORIAL: Burris, H and Weiner, E. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
561. Morrison, V; Wong, M; **Hershman, D**; Campos, L; Ding, B; Malin, J. Variations in Patterns of Care for Colony Stimulating Factors: Implications for the Effectiveness of Filgrastim and Pegfilgrastim in Community Practice. Journal of Managed Care Pharmacy. 2007 May;13(4):337-348.
562. Crew, K; Neugut, AI; Wang, X; Jacobson, J; Grann, V; Raptis, G; **Hershman, D**. Racial Disparities in Treatment and Survival of Male Breast Cancer. Journal of Clinical Oncology. 2007 Mar 20;25(9):1089-1098.
563. **Hershman, D**; Neugut, AI; Jacobson, J; Wang, J; Tsai, W; McBride, R; Bennett, C; Grann, V; Granulocyte colony stimulating factor use during breast cancer adjuvant chemotherapy and acute leukemia risk. Journal of the National Cancer Institute. 2007 Feb 7;99(3):196-205. EDITORIAL Touw, I and Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy
564. **Hershman, D**; Hall, M; Wang, X; Jacobson, J; McBride, R; Grann, V; Neugut AI. Timing of Adjuvant Chemotherapy Initiation following Surgery for Stage III Colon Cancer. CANCER. 2006. Dec 1;107(11):2581-2588.
565. Grann, V; **Hershman, D**; Jacobson, J; Tsai, W; Wang, J; Mitra, N; Grossbard, M; Neugut, A. Diffusion and Outcomes of Doxorubicin-based Chemotherapy among Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. Cancer. 2006 Oct 1;107(7):1530-1541.
566. Sparano, JA; Moulder, S; Kazi, A; Vahdat, L; Li, T; Pellegrino, C; Munster, P; Malafa, M; Lee, D; Hoschander, S; Hopkins, U; **Hershman, D**; Wright, JJ; Sebti, SM. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 2006; Jul 1;24(19):2981-2984. EDITORIAL Rowenski, EK; Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase.
567. **Hershman, D**; Wang, X; McBride, R; Jacobson, J; Grann, V; Neugut, A. Timing of adjuvant radiation therapy after surgery in women with breast cancer. International Journal of Radiation Oncology Biology and Physics. 2006 Aug 1;65(5):1353-1360.
568. Neugut, AI; Matasar, M; Wang, X; McBride, R; Jacobson, J; Grann, V; **Hershman, D**; Early discontinuation of colon cancer treatment and its impact on survival. Journal of Clinical Oncology. 2006 May 20;24(15):2368-2375.
569. **Hershman, D**; Wang, X; McBride, R; Jacobson, J; Grann, V; Neugut, A. Timing of adjuvant chemotherapy after surgery in elderly women with breast cancer. Breast Cancer Res Treat. 2006 Oct;99(3):313-321
570. Villella, J; Cohen, S; Smith, D; Hibshoosh, H; **Hershman, D**. HER-2/neu Over Expression in Uterine Papillary Serous Cancers and its Possible Therapeutic Implications. Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-1902.
571. Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, **Hershman D**, Vahdat LT, Savage DG, Macarthur RB, Hesdorffer C. Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):57-64.
572. Grann, V; Troxel, A; Zojwalla, N; **Hershman, D**; Gleid, SA; Jacobson, J. Regional and racial disparities in breast cancer-specific mortality. Soc Sci Med. 2006 Jan;62(2):337-347.
573. Doyle JJ; Neugut, AI; Jacobson, JS; Grann, VR; **Hershman, DL**. Radiation Therapy and Cardiotoxicity in Older Breast Cancer Patients. International Journal of Radiation Oncology Biology and Physics. 1;68(1):82-93. 2007.

574. Jacobson, J; Grann, V; **Hershman, D**; Troxel, A; Li, H; Neugut, A. Breast Biopsy and Race/ethnicity Among Women without Breast Cancer. Cancer Detect Prev. 2006; 30(2):129-133
575. Anderson, K; Jacobson, J; Heitjan, D; Ziven, J; **Hershman, D**; Neugut, A. Grann, V Impact of Preventive Strategies for Women with BRCA1/2 Mutations: An updated cost-effectiveness study. Annals of Internal Medicine. 2006 Mar 21;144(6):397-406
576. Doyle JJ; Neugut, AI; Jacobson, JS; Grann, VR; **Hershman, D**. Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-based Study. Journal of Clinical Oncology. 2005; Dec 1;23(34):8597-8605.
577. Heck, J; Gorin, S; Alberts, S; **Hershman, D**. Treatment for Breast Cancer among Patients with Alzheimer's. Journal of the American Geriatric Society. 2005 Nov;53(11):1897-1904.
578. **Hershman, D**; McBride, R; Grann, V; Jacobson, J; Roberts, K; Lamerto, L; Neugut, A. Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer. Journal of Clinical Oncology. 2005;\_Sep 20;23(27):6639-6646.
579. Grann, V; Jacobson, J; Troxel, A; **Hershman, D**; Karp, J; Mayers, C; and Neugut, Barriers to Minority Participation in Breast Cancer Prevention Trials, Cancer, 2005, \_Jul 15;104(2):374-379.
580. Grann, V; Troxel, A; Zojwalla, N; Jacobson, J; **Hershman, D**; and Neugut, A. Hormone Receptor Status and Breast Cancer Survival in a Population-based Cohort. Cancer 2005 Jun 1;103(11):2241-2251.
581. Postolov, I; Rasiej, M; **Hershman, D**; Austin, J. Thoracoabdominal Muscular Enlargement: CT Demonstration in Dermatomyositis. AJR Am J Roentgenol. 2005 Mar;184(3 Suppl):S91-93.
582. Crew, D; Cohen, M; Smith, D; **Hershman, D**. Long Natural History of Recurrent Granulosa Cell Tumor of the Ovary 22 Years after Initial Diagnosis: A Case Report and Review of the Literature. Gynecologic Oncology. 2005 Jan;96(1):235-240.
583. **Hershman, D**; Weinberg, M; Rosner, Z; Alexsis K; Tiersten A; Grann, V; Troxel, A; Neugut, A. Ethnic Neutropenia And Treatment Delay In African-American Women Undergoing Chemotherapy For Early-Stage Breast Cancer. Journal of the National Cancer Institute. 95:1545-1548. 2003.
584. **Hershman, D**; Fleischauer, A; Grann, V; Jacobson, J; Mitra, N; Sundararajan, V and Neugut, A; Survival associated with platinum-based Chemotherapy Among Elderly Patients with Stage III and IV Ovarian Cancer. Gynecologic Oncology. 2004 Aug;94(2):540-549.
585. Tiersten, A; Selleck, M; **Hershman, D**; et al. Phase II Study of Topotecan and Paclitaxel for Recurrent, Persistent, or Metastatic Cervical Carcinoma. Gynecologic Oncology. 92(2): 635-638. 2004.
586. Grann, VR. Jacobson, JS. Thomason, D. **Hershman, D**. Heitjan, DF. and Neugut, AI. Impact of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. Journal of Clinical Oncology. May 15 2002: 2520-2529.
587. **Hershman, D**; Fleischauer, A; Grann, V; Jacobson, J; Neugut, A; Variations in use and efficacy of chemotherapy use and for stage II ovarian cancer in the elderly: a population-based study. Gynecologic Oncology. 92(1) 293-299 2004
588. Sundararajan, V; **Hershman, D**; Grann, V; Jacobson, J; Neugut, A; Variations in chemotherapy use for advanced ovarian cancer in the elderly: a population-based study. Journal of Clinical Oncology. 20 (1):173-178, 2002.
589. **Hershman, D**; Sundararajan, V; Jacobson, J; Neugut, A; Grann, V. Benefits of Tamoxifen for the prevention of breast cancer among women with varying risks: A decision analysis. Journal of Clinical Oncology. 20 (1):9-16, 2002. EDITORIAL::Jordan, C; Marrow, M. Chemoprevention of Breast Cancer: A Model for Change. 1-3 2002.
590. Grann, V.; Jacobson, J.; Whang, W.; **Hershman, D**.; Heitjan, D.; Antman, K.; Neugut, A.; Decision analysis of chemoprevention vs prophylactic surgery in BRCA1/2 positive women., Cancer Journal of Scientific American, 2000, 6:13-20.

591. Crystal, H.; Ortof, E.; Frishman, W.; Gruber, A.; **Hershman, D.**; Ironstone, M. Serum vitamin B12 levels and incidence of dementia in a healthy elderly population: A report from the Bronx Aging Study. Journal of the American Geriatric Society. 42:933-936, 1994.
592. **Hershman, D.**; Frishman, W.; Simon off, P; Ironstone, M. Drug utilization in the old old, and how it relates to self-perceived health and all cause mortality: Results from the Bronx Aging Study. Journal of the American Geriatric Society. 42:933-936, 1994.
593. Gerr, F.; Letz, R.; **Hershman, D.** Farraye, J., Simpson, D. Comparison of rapidly determined vibrotactile perception threshold with NCV/EMG and physical examination. Muscle and Nerve. 14:1059-1066; 1991.
594. Franzblau, A.; Letz, R.; **Hershman, D.**; Mason, P.; Wallace, J.; Bekesi, J. Quantitative vibration threshold testing and computer-based neurobehavioral testing of persons infected with HIV. Archives of Neurology. 48:263-268;1991.
595. Gerr, F.; Letz, R.; **Hershman, D.**; Pace, P.; Cherniack, M. Neurovascular symptoms among shipyard workers exposed to hand-arm vibration. Br J Ind Med. 1992 Jan;49(1):53-62.
596. Gerr, F.; **Hershman, D.**; Letz, R. Vibrotactile threshold measurement for detecting neurotoxicity: Reliability and determination of normative values. Archives of Environmental Health. 45(3):148-154; 1990.
597. Letz, R; Mahoney, F.C.; **Hershman, D.**; Woskie, S.; Smith, T.J. Neurobehavioral effects of acute styrene exposure in fiberglass boatbuilders. Neurotoxicology and Teratology, 12:665-668; 1990.

#### **Editorials/Commentaries**

1. Basu A, **Hershman DL**. The "PRO"mise and "PRO"gress of PROs in cancer clinical trials. J Natl Cancer Inst. 2024 Jul 31:djae157. doi: 10.1093/jnci/djae157. Online ahead of print.
2. Crew KD, **Hershman DL**. Better Together: Clinical and Genomic Data to Inform Shared Decision Making. J Clin Oncol. 2020 Dec 11.
3. Schrag D, **Hershman DL**, Basch E. Oncology Practice During the COVID-19 Pandemic. JAMA. 2020 Apr 13
4. Basch E, **Hershman D**, Gurtshaw C, Schweizer AP, Krzyzanowska M. ASCO's Quality Care Symposium and the Evolving Science of Value-Based Care. JCO Oncol Pract. 2020 Mar;16(3):113-114.
5. Loprinzi CL, Lustberg MB, **Hershman DL**, Ruddy KJ. Chemotherapy-induced peripheral neuropathy: ice, compression, both, or neither? Ann Oncol. 2020 Jan;31(1):5-6
6. Loprinzi CL, **Hershman DL**, Staff N, Neuronal Protection for Chemotherapy Neuropathy Prevention? J Natl Cancer Inst. 2019 May 15.
7. **Hershman DL**: Working Hand in Glove to Prevent Chemotherapy Induced Peripheral Neuropathy. Journal of the National Cancer Institute. 2017.
8. **Hershman DL**: Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: The Time Has Come. JAMA. Feb 2017. Volume 317(6).
9. **Hershman DL**: Sticking To It: Improving Outcomes by Increasing Adherence. J Clin Oncol. 2016 Jul 20;34(21):2440-2.
10. **Hershman DL**: Perfecting Breast Cancer Treatment: Is the Pain Worth the Incremental Gain. The New England Journal of Medicine. 2015 Jan 29;372(5):477-8.
11. Wright, JD; **Hershman, DL**; Measure for Measure: the Cost of Improving Quality. Journal of the National Cancer Institute. 2014 Sep 13; 106(10).
12. **Hershman DL**; **Off-Label Cancer Therapy Use: How Much is Too Much?**. Journal of Clinical Oncology. Podcast. Feb 19<sup>th</sup>, 2013.

13. Wright, JD and **Hershman DL**; Comparative effectiveness of robotic gynecologic surgery. Journal of Comparative Effectiveness Research, September 2012, Vol. 1, No. 5, Pages 377-379.
14. Kalinsky, K; **Hershman, DL**; Cracking Open Window of Opportunity Trials. J Clin Oncol. 2012 Jul 20;30(21):2573-5.
15. **Hershman, DL**, Unger, J; Minority Report: How best to analyze clinical trial data to address disparities. Editorial. Breast Cancer Research and Treatment. 2009 Sep 17.
16. **Hershman, DL**, Neugut AI; Anthracycline Cardiotoxicity: One Size Does Not Fit All! Journal of the National Cancer Institute. 2008 Aug 6;100(15):1046-7.
17. **Hershman, DL**; Getting a 'grip' on Aromatase Inhibitor induced Arthralgia. J Clin Oncol. 2008 Jul 1;26(19):3120-1.
18. Neugut, AI; Lebwohl, B; **Hershman, DL**; Cancer chemoprevention: how do we know what works? J Clin Oncol. 2007 Apr 20;25(12):1461-2.

### **Book Chapters / Reviews / Commentaries**

1. **Hershman DL**, Ganz PA. Quality of Care, Including Survivorship Care Plans. Adv Exp Med Biol. 2015;862:255-69.
2. **Hershman DL**, Loprinzi C, Schneider BP. Symptoms: Aromatase Inhibitor Induced Arthralgias. Adv Exp Med Biol. 2015;862:89-100.
3. Schneider BP, **Hershman DL**, Loprinzi C. Symptoms: Chemotherapy-Induced Peripheral Neuropathy. Adv Exp Med Biol. 2015;862:77-87.
4. Kalinsky, K; **Hershman, DL**; Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting. Journal of Comparative Effectiveness. Jul 2013, Vol. 2, No. 4, Pages 393-403.
5. Accordino MK, **Hershman DL** Disparities and challenges in adherence to oral antineoplastic agents. Am Soc Clin Oncol Educ Book. 2013;2013:271-6.
6. **Hershman, DL** and Shao, T; Anthracycline Cardiotoxicity after Breast Cancer Treatment. Oncology. 23(3) 227-34. March 2009.
7. Greenlee, G; **Hershman, DL**; Jacobson, JS. Use of antioxidant supplements during breast cancer treatment: A comprehensive review. Breast Cancer Research and Treatment. 2008 Oct 7.
8. **Hershman, DL**, Chu, C; Crew, KD. Updates in the Management of Menopausal Symptoms. Curr Oncol Rep. 2009 Jan;11(1):29-36.
9. **Hershman, DL**; Cardiac toxicity in elderly patients with diffuse b-cell non-Hodgkin's lymphoma. The American Journal of Hematology/Oncology. Nov 2008;7(11) 505-10
10. Neugut, AI; Jacobson JS; **Hershman, DL**. Reply to: Effect of Breast Cancer Radiotherapy and Cigarette Smoking on Risk of Second Primary Lung Cancer. Journal of Clinical Oncology. 2008.
11. **Hershman, DL**; Commentary on: Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study. Breast Disease Quarterly. 2008.
12. **Hershman, D**. Loprinzi, C. Managing Menopausal Symptoms in Breast Cancer Patients. *Diseases of the Breast*. Fourth Edition. May 2008.
13. **Hershman, DL**, Neugut, AI, Grann, V; Reply to: Granulocyte colony stimulating factor use during breast cancer adjuvant chemotherapy and acute leukemia risk. Journal of the National Cancer Institute. 2007. Jul 4;99(13):1051-2
14. **Hershman, DL**. Commentary on: Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens. Breast Disease Quarterly. 2007.

15. **Hershman, DL.** Commentary on: Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy. *Breast Disease Quarterly*. 2007
16. Adelson, KA, Loprinzi, C and **Hershman, D.** Treatment of Hot Flashes in breast and prostate cancer. *Expert Opin Pharmacother*. 2005 Jun;6(7):1095-106.
17. **Hershman, D.** Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. *Curr Oncol Rep*. 2004 Jul;6(4):277-84.
18. **Hershman, D.** Loprinzi, C. Managing Menopausal Symptoms in Breast Cancer Patients. *Diseases of the Breast*. Third Edition. May 2004.
19. **Hershman, D.** Ritchie, E. Rosner, Z; Cancer Survivorship: Breast and Prostate Cancer. Gender differences in Medicine, April 2004.
20. Questions and Answers about Breast Cancer Metastatic to Bone. The Paget Foundation for Bone Disorders, 2001.
21. Frishman, W.; Murthy, V., Strom, J.; **Hershman, DL.** Ultrashort-acting beta-adrenoceptor blocking drug: Esmolol. In Messerli, F. *Cardiovascular Drug Therapy*, Philadelphia, Second Edition, 1994.
22. Frishman, W.; Murthy, V., Strom, J.; **Hershman, DL.** Ultrashort-acting beta-adrenoceptor blocking drug: Esmolol. In Messerli, F. *Cardiovascular Drug Therapy*, Philadelphia, Second Edition, 1994.

#### **INVITED AND/OR PEER-SELECTED PRESENTATIONS AT REGIONAL, NATIONAL OR INTERNATIONAL LEVELS:**

##### **INVITED PRESENTATIONS:**

1. Hormone Deprivation syndromes. American Society of Clinical Oncology Symposium on supportive care in oncology. Florida. 2002.
2. Bone Loss in breast and prostate cancer. Mayo Clinic. Amilia Island. Florida. 2002.
3. Cancer Survivorship in Breast and Prostate Cancer Patients. Paul Marks Symposium. Connecticut. 2003.
4. Treatment related bone loss in breast cancer patients: St. Barnibus Cancer Survivorship Symposium. New Jersey. 2004.
5. New Treatments for Breast Cancer: Aromatase Inhibitors: General Medical Grand Rounds. Mount Sinai Hospital. New York. 2004.
6. Maximizing the effectiveness of adjuvant chemotherapy. Oncology Grand Rounds. Valley Hospital. New Jersey. 2004
7. Adjuvant Therapy with Aromatase Inhibitors. Columbia University CME. Updates in Breast Cancer. New York. 2004
8. Cancer related bone loss. Metropolitan Breast Cancer Group. New York. 2004.
9. Adjuvant Hormonal Therapy, Columbia University. General Medicine Conference. New York. 2004.
10. Breast Cancer Survivorship. Women at Risk Breast Cancer Symposium. New York. 2004
11. Adjuvant Breast Cancer Treatment: Race, Dose and Survival. Department of Medicine Grand Rounds. Columbia University. 2005.
12. Racial Disparities in Breast Cancer Treatment. Breast Cancer in women of color. New York. 2005
13. Disparities in cancer outcomes, NCI Press Conference/Webcast, 2005
14. SWOG Scientific Symposium: Admixture studies in the cooperative group. Panelist. 2006.
15. Racial/Ethnic disparities in cancer treatment, AACR, Charlston SC, 2006
16. Disparities in Quality of Cancer Care, Saint Lukes Rosevelt Hospital, 2006

17. Breast Cancer Survivorship, SHARE, New York. 2006.
18. Breast Cancer Survivorship: Understanding Acute and Long Term Effects of Treatment, Paul Marks Oncology Symposium, Connecticut. 2006
19. New York Cancer Consortium: Phase II Neoadjuvant studies in breast cancer, New York, 2007.
20. Disparities in Quality of Cancer Care. AACR Health Disparities Conference. Invited Speaker. Atlanta. 2007
21. SWOG Scientific Symposium: Cancer Survivorship Research in the Cooperative Groups. Chicago. 2007
22. Bone loss in cancer survivors: Endocrinology Grand Rounds. CUMC. 2007
23. Breast Cancer Survivorship: Understanding Acute and Long Term Effects of Treatment. Medical Oncology Grand Rounds. 2008
24. Late Effects of Cancer Therapy. American Cancer Society. New York. 2008
25. Late Effects of Cancer Therapy. SHARE. New York. 2008
26. Breast Cancer Survivorship: Understanding Acute and Long Term Effects of Treatment. Dana Farber Cancer Institute. Boston. Mass. 2008
27. Co-Chair. Era of Hope Symposium. Health Outcome in Breast Cancer. Baltimore, Maryland. 2008
28. Breast Cancer Survivorship: Understanding Acute and Long Term Effects of Treatment. Fred Hutchinson Cancer Institute, Seattle, Washington. 2008
29. Breast Cancer: Quality of Care, Survivorship and Late Effects. Department of Medicine Grand Rounds. Columbia University Medical Center. 2008
30. Early Stage Breast Cancer: Advances in Prognostic and Predictive Tools to Aid Decision Making. Current Clinical Issues in Primary Care. New York. 2008.
31. Predicting and Treating Taxane Neuropathy. Cancer Survivorship Conference, Ohio, 2009.
32. Neuropathy Trials Overview. Chemotherapy Induced Peripheral Neuropathy Clinical Trials Planning Committee. NCI. Rockville. 2009
33. Host factors and toxicity in breast cancer survivors. "From Molecular Tumor Markers to Health Behaviors – Promises and Challenges of Cancer Survivorship" Special Session. AACR. 2009.
34. Physical, Psychological and Cognitive Challenges of Long Term Survivors. Education Session ASCO 2009
35. Discussant: ASCO – Health Services Research Oral Session. ASCO 2010.
36. Discussant: SABCS – Symptoms Control/Lifestyle. SABCS 2010.
37. Discussant ASCO – Breast Oral Session. ASCO Chicago, 2011
38. Treatment for Aromatase Inhibitor Arthralgias. ECOG Breast Committee Meeting.
39. Improving Aromatase Inhibitor Adherence. Harry Hines Symposium, 2011
40. Supportive Care in Oncology, Role of acupuncture in supportive care, Chicago, 2012
41. Discussant SABCS – Cancer Survivorship, Texas, 2011
42. Discussant ASCO – Cancer Prevention and Epidemiology, Chicago, 2012
43. Cardiovascular Complications of Anticancer Drugs, Education Session, ASCO, Chicago, 2012
44. Prevention of chemotherapy induced peripheral neuropathy, MASCC Symposium, NY 2012
45. Discussant SABCS – Breast Cancer Disparities, Texas, 2012
46. Breast Cancer in Era of Personalized Medicine, Grand Rounds, OB-GYN, CUMC, 2013.

47. Adherence to oral cancer therapy, ASCO 2013.
48. Discussant ASCO – Cost of Cancer Care, June, 2013
49. Cancer Survivorship, NYPH Oncology Board Review, New York, October 2013
50. Integrative Oncology, School of Breast Oncology, Atlanta, November 2013
51. Quality of care and Toxicity, Roswell Park Cancer Institute, November 2013,
52. Energy Balance, SABCS Discussion Session Chair, SABCS 2013.
53. Generic Aromatase Inhibitor Therapy and Adherence, Oral Presentation, SABCS 2013.
54. Hype or Hope: Repurposing medications for cancer prevention and treatment, ASCO 2014
55. Late Effects of Breast Cancer Therapy. Discussant. SABC 2014.
56. Improving Quality through Organizational Structures. ASCO, Chicago, 2015
57. Key Note Speaker, Conquer Cancer Foundation Research Retreat, Washington, 2015.
58. Improving the Quality of Breast Cancer Care, Dana Farber Cancer Institute, 2016
59. Translational Outcomes Research, Yale New Haven Cancer Center, 2016
60. Improving the Quality of Breast Cancer Care, Cancer Institute New Jersey, Distinguished Speaker. 2017
61. Improving the Quality of Breast Cancer Care, MDACC. 2017
62. Improving the Quality of Cancer Care, MSKCC. 2017
63. Improving the Quality of Cancer Care, Mount Sinai Medical Center. 2018
64. Schlager lecturer: Breast Cancer: New Horizons, Current Controversies, Dana Faber. 2018
65. Living Well with Breast Cancer: NY Metastatic Breast Cancer Conference. Susan G. Komen Greater New York. 2018
66. Improving the Quality of Cancer Care, Huntsman Cancer Center, 2018
67. Evaluating the safety and efficacy of integrative approaches for cancer survivors, Society of Integrative Oncology, 2019
68. Medication Adherence in Cancer Patients, Dana Farber Cancer Institute. 2020
69. Medication Adherence in Cancer Patients, Medical Grand Rounds, University of Wisconsin. 2020
70. National Academy of Medicine Panel: Improving the Evidence Base for Older Adults with Cancer, 2021
71. Improving the Quality of Cancer Care, Yale Cancer Center 2022
72. Improving the Quality of Cancer Care, Johns Hopkins Cancer Center, 2022
73. Clinical Trials to Inform Evidence Based Integrative Therapy, MSKCC, 2024
74. Improving the Quality of Cancer Care, CUIMC Department of Medicine Grand Rounds, 2025

#### **SELECT ORAL ABSTRACTS/PLENARY:**

Hershman DL, Neugut AI, Buono D, Richards CA, Glied SA, Wright JD. Off-label and compendia use of chemotherapy in patients with metastatic cancer. Clinical Science Symposium. Oral Session ASCO 2013

Wright JD, Neugut AI, Siddiq Z, Glied SA, **Hershman DL**; Use of high-intensity surveillance in patients following a diagnosis of stage I-II non-small cell lung cancer. ASCO Oral Session 2011

Hershman, DL; Subar, M; Wilde, E; Stratton, S; Brouse, C; Hillyer, G; Grann, VR; **Neugut AI**. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early stage breast cancer. SABCS Oral Plenary 2009.

**Hershman, DL**; Neugut, AI; Richards, CA; Kalinsky, K; Charles, AS; Wright, JD. Influence of hospital factors, physician factors and type of health insurance on receipt of immediate post mastectomy reconstruction in young women with breast cancer. SABCS Oral Plenary, 2010.

**Hershman DL**, Tsui J, Meyer J, Glied S, Hillyer, G, Wright DW, Neugut AI. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. SABCS Oral Plenary, 2013.

Wright JD, Tergas A, Lewin S, Burke W, Chen L, Neugut AI, **Hershman DL**. Relationship between surgical oncologic outcomes and publically reported hospital quality measures. ASCO Oral Session 2014

**Hershman DL**; Unger JM; Wright JD, Ramsey S; Till C; Tangen CM, Barlow W, Blanke C, Thompson I, Hussain M. Long Term Consequences of Intermittent and Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer. ASCO Oral Session 2015.

**Hershman DL**; Till C; Wright JD, Awad D, Ramsey S; Barlow WE; Minasian L; Unger JM. Comorbidities and Risk of Chemotherapy Induced Peripheral Neuropathy Among Participants 65 or Older in SWOG Clinical Trials. ASCO Oral Session 2016.

**Hershman DL**, Unger JM, GreenleeH, Capodice J, Lew DL, Darke A, Kengla A, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200). SABCS Oral Plenary Session, 2017.

**Hershman, DL**, Unger, JM, Hillyer, GC, Moseley, A, Arnold, KB, Dakhil, SR, Esparaz, BT, Kuan, MC, Graham, ML, Lackowski, DM, Edenfield, WJ, Dayao, ZR, Gralow, J, Ramsey, SD, Neugut, AI; Randomized Trial Of Text-Messaging To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer: Swog S1105, Nct01515800. ASCO Oral Abstract Session. 2019

**Hershman, DL**; Till, CT; Wright, JD; Accordino, M; Vaidya, R; Barlow, WE; Ramsey, SD, Unger, JM. The Association of Baseline Cardiovascular Risk Factors and Healthcare Utilization and Costs in Elderly Breast Cancer Patients Enrolled in SWOG Clinical Trials. ASCO Oral Abstract Session. 2019

#### **ABSTRACTS (UPON REQUEST)**